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Abstract
The multi-component kinase mTOR complex 1 (mTORC 1) coordinates nutrient and
growth factor inputs with numerous downstream processes including protein translation,
autophagy, metabolism and cell growth. We have found that inhibition of mTORC 1 with
rapamycin treatment suppressed whole-body postnatal growth similar to reduced caloric
intake. We found that while feeding activated mTORC 1 in almost every tissue, there was
variability in the upstream activating stimuli. The role of mTORCl in organ growth was
further elucidated by studies we performed using liver-specific mTORC1 gain and loss of
function mutants. Confirming our studies with rapamycin, genetic activation or
suppression of mTORC 1 increased and decreased liver size respectively, and rendered
the liver insensitive to nutrients. Rendering the liver insensitive to nutrients also had
functional consequences. In response to starvation, the liver shifts to fatty acid catabolism
and generates ketone bodies to supplement lowered glucose levels. We find that
constitutive activation of mTORC1 prevents the liver from initiating fatty-acid oxidation
and ketone production in response to fasting. Many aspects of the hepatic fasting
response malfunction in old age including fatty acid catabolism and ketogenesis. We find
this aging-dependent process is mediated by mTORC 1, and thus loss of mTORC 1
function throughout the adult life of the animal prevents the aging induced decrease in
hepatic ketogenesis. As such, pharmaceutical inhibition of mTORC 1 may be beneficial in
battling metabolic disorders due to aging. Pharmaceutical inhibition of mTORC is a
potential treatment for patients suffering from tuberous sclerosis complex (TSC). The
disease TSC in humans is initiated by loss of TSC1 or TSC2, which results in hyper-
active mTORC 1 activity. The disease can involve development of multiple lesions
including brain harmatomas, angiomyolipomas (AMLs), and lymphangioleiomyomatosis
(LAM). We have engineered transgenic mice that express Rheb2, an mTORC 1 activator,
in a doxycycline-inducible manner. Overexpression of Rheb2 led to cystic growths with
characteristics of both LAM and AML. We hope this mouse model will be helpful in
furthering our understanding of the pathology behind these lesions, and provide a mouse
model for therapeutic intervention for TSC.
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Chapter 1
Introduction
Introduction
In multicellular organisms, it is imperative that organismal growth and
metabolism be continually coordinated with nutrient status. As a result, a highly complex
multi-layered system has evolved by which nutritional status is sensed, communicated
systemically, and buffered throughout the lifespan of an organism. The highly conserved
kinase target of rapamycin (TOR) plays an essential role in coordinating cellular growth
and metabolism with nutrients and energy. TOR nucleates at least two distinct
complexes: complex 1 (TORC1) and complex 2 (TORC2). While insulin and growth
factors activate both TORC1 and TORC2, nutrients such as amino acids and glucose
activate only TORC1. Both complexes, when active, collaborate to promote pro-growth
programs such as mRNA translation. Furthermore, active TORCI suppresses insulin
signaling through a negative feedback loop, while TORC2 promotes the presence of
nutrient transporters at the cell surface and cell survival.
In mammals, mutations within the mTORC1 and mTORC1 signaling network
result in a wide range of pathologies. Hyper-activation of mTORC1 is the defining insult
in Tuberous Sclerosis Complex (TSC). TSC is characterized by benign lesions in
multiple tissues that can lead to organ failure and increased mortality. Here we describe a
new mouse model for angiomyolipoma and lymphangioleiomyomatosis, two lesions
found in the majority of TSC patients. Analysis of the mouse model reveals a role for
mast cells in the progression of these devastating lesions.
Perturbations in mTOR signaling also have a large impact on cellular and
organismal growth and metabolism. We demonstrate that inhibition of mTORC1
function by treatment with rapamycin inhibits postnatal growth via the same mechanism
as dietary restriction. Rapamycin suppresses the postnatal growth of every tissue
measured, and subsequent analysis finds that mTORC1 activity in numerous tissues is
sensitive to feeding. Further analysis reveals tissue-dependent diversity in the upstream
stimuli that activate mTORC1 upon refeeding.
To understand the role mTORC1 plays in adult organ physiology, we studied
mice with both mTORC1 loss and gain of function mutations specifically in the liver.
We subjected the mutant mice to fasting and refeeding regimens and examined the effect
of perturbing mTORC1 signaling on the hepatic response to both conditions. In response
to fasting, the liver produces glucose, ketones and ATP essential for the adaptive
response of the entire organism. We find mTORC1 negatively regulates hepatic fatty
acid oxidation and subsequent conversion into ketones in response to fasting. The
increase in fatty acid oxidation and ketone synthesis in the liver upon fasting is mediated
by the actions of the nuclear receptor peroxisome proliferators-activated receptor alpha
(PPARoc). We find that mTORC1 inhibits the transcriptional ability of PPARoc. As a
result, mice with an mTORC 1 gain of function mutation in their livers produced
dramatically reduced levels of ketones upon fasting.
In rodents, aging induces defects in the hepatic fasting response that are correlated
with decreased PPARoc transcription and ketone synthesis (Durnas et al., 1990). We find
that aging suppresses PPARoc via mTORC1. Mice with a hepatic mTORC1 loss of
function mutation are protected from the aging-related decline in ketogenesis and
PPARoc activity.
The use of mouse models to probe mTORC1 biology has revealed an astonishing
wide range of functions for the kinase- from disease pathology to lipid metabolism to
regulation of aging. The diversity of results described from our work underscores the
need for additional research dissecting tissue-specific roles for mTORC1, and may also
help clarify the pleiotropic and inconsistent affects of rapamycin use in the clinic. The
following introduction focuses on mammalian TOR (mTOR) biology with emphasis on
the role of mTOR Complex 1 (mTORC1) in organismal growth, metabolism and disease.
Discovery of mTOR
Cell growth (an increase in mass) takes precedence over cell proliferation. Genetic
mutations that increase cell proliferation but do not promote cell growth lead to smaller
and smaller cells. As a result, a cell must always sense its mass to know when to divide.
This fundamental aspect of biology, the regulation and sensing of cellular mass, is
modulated by the external environment and impinges upon every cellular process. The
ancient kinase target of rapamycin (TOR) is a master regulator of cell size, and its
relatively recent discovery underscores how little we know about the molecular processes
behind the fundamental process of cell growth. Research into TOR function arose from
attempts to understand the molecular mechanism behind the drug rapamycin and its anti-
fungal (Singh et al., 1979) and anti-tumor properties (Eng et al., 1984). The discovery
that rapamycin is also a potent immunosuppressant with low toxicity (Morris et al., 1989)
accelerated the search for its cellular target. Treatment with rapamycin leads to a
decrease in cell size in both yeast and mammalian cells. It also induces cell cycle arrest
in yeast and in some mammalian cells. Using genetic screens in yeast and biochemical
purifications in mammalian cells, rapamycin was found to bind the peptidyl-prolyl
isomerase FK506 binding protein 12 (FKBP12). The resulting drug/protein complex
binds and allosterically inhibits mTOR kinase activity (Bierer et al., 1990);(Heitman et
al., 1991); (Brown et al., 1994); (Sabatini et al., 1994). mTOR is a 289-kDa serine-
threonine kinase and belongs to the phosphoinositide-3-kinase (PI3K)-related kinases
(PIKK) family along with ATM, ATR, DNA-PK and hSMG1. All kinases have C-
terminal kinase domains similar to PI3K, thus giving the family its name. While all
members of the family respond to genotoxic stress, mTOR has evolved to also sense
hypoxia, nutrients and growth factors.
Components of mTOR complexes
We now group mTOR into two distinct complexes called complex 1 and complex
2. Although both contain mTOR kinase, each complex has unique binding partners that
allow for different activating upstream signals and different downstream substrates. In
multicellular organisms, both complexes respond to growth factor and hormonal input,
while only complex 1 (mTORC1) responds to the presence of nutrients such as amino
acids and glucose. mTORC1 is also the direct target for inhibition by rapamycin.
mTORC1 has four components in addition to mTOR: regulatory-associated protein of
mTOR (Raptor); mammalian lethal with Secl3 protein 8 (mLST8, also known as GPL);
proline-rich AKT substrate 40 kDa (PRAS40); and DEP-domain-containing mTOR-
interacting protein (Deptor). The functional role for each of these proteins within
mTORC1 is still being actively researched. Raptor seems to regulate mTORC1 assembly
and helps recruit mTORC1 substrates such as S6K (Kim et al., 2002). The role of
mLST8 remains unclear, for deletion of the gene has no affect on mTORC1 activity in
vivo (Guertin et al., 2006). PRAS40 and Deptor directly bind to mTORC1 and inhibit
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kinase activity. During activating conditions, mTORC1 phosphorylates both PRAS40
and Deptor; this causes their disassociation and leads to increased mTORC1 catalytic
activity (Sancak et al., 2007);(Peterson et al., 2009).
mTORC2 shares several proteins with mTORC1 such as mTOR, mLST8 and
Deptor. However, mTORC2 also contains several unique components: rapamycin-
insensitive companion of mTOR (Rictor), mammalian stress-activated protein kinase
interacting protein (mSIN1), and protein observed with Rictor-1 (Protor-1). Rictor and
mSIN1 help stabilize each other, and thus may provide structural integrity to mTORC2
(Frias et al., 2006; Jacinto et al., 2006). There has been no clear mTORC2 function
ascribed to Protor-1 other than its interaction with Rictor (Thedieck et al., 2007). In
contrast to mTORC 1, mLST8 is required for mTORC2 catalytic activity in vivo (Guertin
et al., 2006). However, similar to mTORC1, Deptor also serves as an endogenous
inhibitor to mTORC2 (Peterson et al., 2009). The research results described in this thesis
involve mTORC1 biology primarily, so the remainder of the introduction will focus on
upstream and downstream signaling of mTORC1, as well as its role in growth,
metabolism and disease.
Upstream of mTORC1
Four distinct signals are sensed by mTORC1: growth factors, energy status,
oxygen and amino acids. All of these inputs, with the exception of amino acids, converge
upon the Tuberous Sclerosis Complex (TSC), which is a heterodimer consisting of the
proteins TSC1 (also known as hamartin) and TSC2 (also known as tuberin). The TSC1/2
heterodimer acts as a GTPase activating protein (GAP) for the small GTPase Rheb (Ras
homolog enriched in brain) (Tee et al., 2003). Rheb, bound to GTP, positively regulates
mTORC1 by direct interaction, although the exact mechanism behind the interaction is
unclear (Long et al., 2005; Sancak et al., 2007). As such, active TSC is an inhibitor of
mTORC1 by catalyzing the conversion of Rheb-GTP to Rheb-GDP (Inoki et al., 2003).
Growth Factors
Growth factors activate mTORC1 via the canonical PI3K and Ras pathways.
Stimulation of these pathways leads to phosphorylation of TSC2 by AKT (Potter et al.,
2002), extracellular-signal-regulated kinase 1/2 (ERK1/2) (Ma and Blenis, 2009), and by
p90 ribosomal S6 kinase 1 (RSK1) (Roux et al., 2004). All of these phosphorylations
inhibit the GAP activity of TSC, thus relieving its inhibition of mTORC1. AKT is also
able to activate mTORC1 independently of TSC by phosphorylating and inactiving
PRAS40 (Sancak et al., 2007).
The negative feedback loop
The hormone insulin is an important physiologically activator of mTORC1.
When insulin binds its cognate tyrosine kinase receptor, insulin receptor substrate 1
(IRS 1) is recruited to the receptor and activates phosphoinositide 3-kinase (PI3K). PI3K
activation produces phosphatidylinositol (3,4,5)-triphosphate [PtdIns(3,4,5)P 3] which
recruits Protein Kinase B (PKB/AKT) to the plasma membrane leading to its activation.
mTORC1 is activated by AKT via phosphorylation of TSC and PRAS40. mTORC1 also
limits insulin signaling via a negative feedback loop, mediated by the mTORC 1 substrate
ribosomal S6 kinase 1 (S6K1). S6K1, once activated by mTORC1, can phosphorylate
IRS 1, which promotes its degradation (Harrington et al., 2005). Given the role of insulin
and insulin-related growth factors in metabolic disorders and cancer, this potent negative
feedback loop between mTORC 1 and insulin signaling has broad clinical implications.
Furthermore, it seems that activated mTORC1 can suppress the activity of other growth
factor receptors that do not rely on IRS 1, such as platelet-derived growth factor receptor
(PDGFR) (Zhang et al., 2007). While the mechanism behind this negative feedback loop
is unclear, it indicates that nature has created a paradigm by which mTORC1 not only
senses growth factor input, but can also limit the duration of growth factor induced
cellular programs.
Energy status
Low ratio of ATP to ADP results in activation of AMP-activated protein kinase
(AMPK), a master sensor of intracellular energy status (Hardie, 2007). When activated,
AMPK directly phosphorylates TSC2, increasing GAP activity towards Rheb and thus
inhibiting mTORC1 (Inoki et al., 2003). In addition, active AMPK can phosphorylate
Raptor, thus inhibiting mTORC1 through an unknown mechanism (Gwinn et al., 2008).
Hypoxia
Hypoxia inhibits mTORC1 through multiple mechanisms. Hypoxia reduces ATP
levels, thus repressing mTORC1 activity via the mechanism described above (Wouters
and Koritzinsky, 2008). Hypoxia also inhibits mTORC1 through transcriptional
regulation of DNA damage response 1 (REDD1) (Reiling and Hafen, 2004). REDD1
inhibits mTORC1 via TSC2. REDD1 activates TSC2 by stimulating the its dissociation
from 14-3-3 proteins (DeYoung et al., 2008). Additionally, during hypoxia,
promyelocytic leukemia (PML) tumor suppressor and BCL2/adenovirus E1B 19 kDa
protein-interacting protein 3 (BNIP3) reduce mTORC1 signaling by disrupting the
interaction between mTOR and its positive regulator Rheb (Bernardi et al., 2006).
Amino acids
Amino acid activation of mTORC1 represents a highly conserved role for TOR
found in almost all eukaryotes. In keeping with this ancient role, regulation of mTORC1
by amino acids is independent of TSC, for mTORC1 activity remains sensitive to amino
acids in cells lacking TSC1 or TSC2 (Nobukuni et al., 2005). The regulation of
mTORC1 by amino acids remained elusive until the identification of the role of Rag
proteins in mediating amino acid sensing by mTOR (Sancak et al., 2008). The Rag
proteins are four small GTPases that form heterodimeric complexes, which are present at
endosomal membranes. In response to amino acids, they recruit mTORC1 to the
membrane surfaces via interactions with Raptor. This localization is not only necessary
for amino acid activation of mTORC1; it is also sufficient to activate mTORC1 in the
absence of amino acids. While the interaction between mTORC1 and Rheb is also
required for mTORC1 activation, it is unclear how amino acid deprivation leads to
dissociation of mTORC1 from Rheb. This disruption between Rheb and mTORC1 due to
amino acid deprivation may explain why amino acids are required for growth factor
activation of mTORC1 (Sancak et al., 2008).
Other nutrients
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In addition to amino acids, glucose has been shown to activate mTORC1 in the I-
cells of the pancreatic islets also in an amino-dependent manner. There has also been
evidence that mTORC1 may also sense lipid levels. Phosphatidic acid (PA), which can
be generated either from hydrolysis of phosphatidylcholine by phospholipase D,
acetylation of lysophosphatidic acid (LPA) by LPA acyltransferase (LPAAT), or
phosphorylation of diacylglycerol by diacylglycerol kinase can activate mTORC1 in a
TSC1/2-independent manner (Foster, 2007). While PA is a ubiquitous metabolite, there
is evidence that it is a direct sensor and regulator of phospholipid metabolism and
biosynthesis (Loewen et al., 2004). One could even extrapolate and hypothesize that cell
size, as a function of membrane content, could be sensed by mTORC1 via PA.
Other cellular conditions
As with all PIKK family of kinases, genotoxic stress activates mTOR, although
somewhat indirectly. For instance, the activation of p53 in response to DNA damage
rapidly activates AMPK through an unknown process, which in turn phosphorylates and
thereby activates TSC2 (Feng et al., 2005). p5 3 can also increase the transcription of
phosphatase and tensin homolog deleted on chromosome 10 (PTEN), an inhibitor of
PI3K, and TSC2 (Feng et al., 2005). Pro-inflammatory cytokines such as TNFa activate
IKB kinase- (IKKI), which in turn physically interacts with and consequently inhibits
TSC1 leading to activation of mTORC1 (Lee et al., 2007). This positive relationship
between inflammation and mTORC1 activation is thought to be important in tumor
angiogenesis (Lee et al., 2007) and in the development of insulin resistance (Lee et al.,
2008).
Downstream actions of mTORC1
In response to the wide range of upstream inputs, mTORC1 positively regulates
cell growth and proliferation by promoting many anabolic processes, including
biosynthesis of proteins, lipids and organelles, and by limiting catabolic processes such as
autophagy. The use of rapamycin to mimic loss of mTORC1 function has been an
invaluable tool in revealing downstream mTORC1-dependent processes. However, as
recent work from our lab and others have demonstrated that rapamycin does not inhibit
all functions of mTORC1 (Choo AY, Blenis J; Thoreen CT), additional analysis of
genetic mutants of mTORC 1 is needed to obtain a full picture of mTORC1 biology.
Protein synthesis
The two best characterized substrates of mTORC1, eukaryotic initiation factor 4E
(eIF4E)-binding protein 1 (4E-BP1) and p70 ribosomal S6 kinase 1 (S6K1), have
important roles in the positive regulation of protein synthesis by mTORC1. The
phosphorylation of 4E-BP1 by mTORC1 prevents its binding to eIF4E, enabling eIF4E to
promote cap-dependent translation (Richter and Sonenberg, 2005). The stimulation of
S6K1 activity by mTORC1 leads to increases in mRNA biogenesis, cap-dependent
translation and elongation, and the translation of ribosomal proteins through regulation of
the activity of many proteins, such as S6K1 aly/REF-like target (SKAR), programmed
cell death 4 (PDCD4), eukaryotic elongation factor 2 kinase (eEF2K) and ribosomal
protein S6 (Ma and Blenis, 2009). The activation of mTORC1 has also been shown to
promote ribosome biogenesis by stimulating the transcription of ribosomal RNA through
a process involving the protein phosphatase 2A (PP2A) and the transcription initiation
factor IA (TIF-IA) (Mayer et al., 2004).
Autophagy
When nutrient availability is limited, organelles and protein complexes are
degraded en masse via autophagy. Autophagy involves the de novo synthesis of
membrane bound vesicles, termed autophagosomes, which sequester intra-cellular
components and deliver them to lysosomes via membrane fusion. Lysosomal
degradation of these components liberates biological material to sustain macromolecule
biosynthesis and energy production. The inhibition of mTORC1 triggers autophagy,
whereas stimulation of mTORC1 reduces this process (Codogno and Meijer, 2005).
mTORC1 represses autophagy by phosphorylating multiple components of a protein
complex composed of unc-5 1-like kinase 1 (ULK1), autophagy-related gene 13 (ATG13)
and focal adhesion kinase family-interacting protein of 200 kDa (FIP200) (Ganley et al.,
2009).
Lipid synthesis
Cell growth and proliferation must be coordinated with lipid and phospholipids
biosynthesis. As such, one would expect mTORC1 to regulate these processes as a
master regulator of cell growth. However, the role of mTORC1 in lipid metabolism and
synthesis has only recently been appreciated. It has been demonstrated that AKT-
dependent lipogenesis requires that mTORC 1 positively regulates the activity of sterol
regulatory element binding protein 1 (SREBP1). Silencing of dSREBP1 in flies results in
reduced cell and organ size which is refractory to dPI3K-induced growth (Porstmann et
al., 2008).
mTORC1 inhibits 3T3-L1 preadipocyte differentiation by suppressing the
expression and transactivation activity of of peroxisome proliferator-activated receptor y
(PPARy)- the master regulator of adipogenesis (Kim and Chen, 2004). Kim and Chen
found that PPARy activity is dependent on amino acid sufficiency. This result is
consistent with the role of mTORC1 coordinating multiple nutrient inputs with cell
growth. Additionally, rapamycin reduces the phosphorylation of lipin-1 (Huffman et al.,
2002), a phosphatidic acid (PA) phosphatase that is involved in glycerolipid synthesis
and in the coactivation of many transcription factors linked to lipid metabolism, including
PPARoc, PPARy and PGC1 oc. Whether lipin-1 is a direct substrate of mTORC1, and
whether it is involved both upstream of mTORC1 through PA production and
downstream of mTORC1 in mediating transcription factors is still unclear.
Mitochondrial metabolism and biogenesis
Given that multiple oxidative pathways and the bulk of cellular ATP synthesis
occurs in the mitochondria, the discovery that mTORC1 regulates mitochondrial
metabolism and biogenesis is not surprising. Inhibition of mTORC1 by rapamycin
lowers mitochondrial membrane potential, oxygen consumption and cellular ATP levels,
and profoundly alters the mitochondrial phosphoproteome (Schieke et al., 2006).
Conversely, hyper-activation of mTORC1 results in increased mitochondrial DNA copy
number, as well as the expression of many genes encoding proteins involved in oxidative
metabolism (Cunningham et al., 2007). Additionally, conditional deletion of Raptor in
mouse skeletal muscle reduces the expression of genes involved in mitochondrial
biogenesis (Bentzinger et al., 2008). Cunningham and colleagues have discovered that
mTORC1 controls the transcriptional activity of PPARy coactivator 1 (PGC1 oc), a
nuclear cofactor that plays a key role in mitochondrial biogenesis and oxidative
metabolism, by directly altering its physical interaction with another transcription factor,
namely yin-yang 1 (YY1) (Cunningham et al., 2007).
mTORC1 in the clinic
The mTORC1 inhibitor rapamycin is used successfully in the clinic as a
immunosuppressant, and in preventing restenosis following angioplasty. Because,
mTORC1 resides within a signaling network littered with tumor suppressors and
oncogenes, there has been considerable anticipation for rapamycin as part of anti-tumor
therapy. Furthermore, as mTORC1 plays a key role in insulin signaling, rapamycin is
also a potential therapeutic for metabolic disorders. Outlined below is a brief description
of the uses of rapamycin in these various disorders, and what can be gained from its
successes and failures.
Rapamycin as an immunosuppressant
mTOR inhibition by rapamycin has shown promise as a therapeutic strategy for
the prevention of transplant rejection and the treatment of autoimmune disease. In renal
transplantation, rapamycin is a powerful anti-rejection agent when used in combination
with other immunosuppressive agents. Not only does rapamycin have unique anti-
atherogenic and anti-neoplastic properties that distinguish it from other anti-rejection
drugs, but it also can promote tolerance and decrease the incidence of chronic allograft
nephropathy (Augustine et al., 2007).
The success of rapamycin treatment of transplant patients is due to selective yet
broad inhibition of numerous types of immune cells. For example, rapamycin inhibits
differentiation of DCs and helps promote their apoptosis (Woltman et al., 2001).
Dendritic cells (DCs) are phagocytic cells that reside in almost all tissues. DCs degrade
pathogens, release cytokines and activate T-cells. Therefore, rapamycin inhibition of
DCs leads to decreased secretion of cytokines and the inability to activate T-cells through
presentation of antigens. Rapamycin is also able to interfere with endocytosis in
macrophages and DCs, thus interfering with their ability to take up antigens (Hackstein et
al., 2002).
In rodents, inhibition of mTOR by rapamycin causes involution of the thymus due
to decreased T-cell proliferation (Song et al., 2007). While this decreases overall T-cell
output, it does not affect production of T-regulatory cells. This is crucial, for T regulator
cells suppress both autoimmune and excessive inflammatory responses. This particular
consequence of rapamycin allows for potent immunosuppression without sacrifice of
immune surveillance against self-antigens and triggering of excessive inflammation
(Sakaguchi et al., 2008). In addition to effector T cells and APCs, rapamycin also
inhibits proliferation and/or function of B-cells, natural killer cells, neutrophils, and mast
cells. The effect of rapamycin on multiple yet select immune cells allows for broad
immunosuppression with limited side effects.
mTOR and cancer
Given its anti-proliferative effects in yeast, there was excitement over the
potential of rapamycin as an anti-tumor drug. With the discovery of mTORC 1 and its
placement downstream of AKT, the excitement increased; many cancers have genetic
mutations that upregulate PI3K signaling, and therefore then depend upon activation of
the oncoprotein AKT. With mTORC1 activity being regulated by AKT, it was predicted
that rapamycin inhibition of mTORC1 would attenuate some of the growth and
proliferative promoting actions of AKT. Indeed the use of rapamycin and its analogues
has had modest successes in the treatment of mantle cell lymphoma, endometrial cancer,
and renal cell carcinoma (Faivre et al., 2006). However, the therapeutic response to
rapamycin is highly variable, suggesting that biomarkers capable of predicting cellular
responses to rapamycin are needed.
The variable response of tumors to rapamycin has engendered a debate on
whether mTORC1 activation or inhibition is more beneficial to cancer cells. The tumor
microenvironment is commonly low on nutrients, energy, and oxygen, so cells insensitive
to these stresses may have a growth advantage. But does this imply constitutive
inactivation or activation of mTORC1? Inactive mTORC1 signaling may initially restrict
the growth of transformed cells in a suboptimal environment. Slower growth may allow
these cells to acquire other mutations and/or await angiogenesis. Indeed, in poor nutrient
conditions, hyper-activation of mTORC signaling could lead to unrestricted growth in,
causing cells to deplete their energy stores and induce apoptosis. Consistent with this
idea, TSC2-deficient cells undergo apoptosis in glucose-free medium, a response
suppressed by rapamycin (Inoki et al., 2003). Inhibition of mTORC1 may also help
tumor cells cope with nutrient deprivation by triggering autophagy, thus allowing the cell
to obtain nutrients autonomously (Lee et al., 2009). This line of evidence would indicate
that inhibition of mTORC1 would actually help tumorigenesis.
The discovery that prolonged exposure to rapamycin decreases AKT S473
phosphorylation in a subset of cancer cells (Sarbassov et al., 2006) changes our
interpretation of rapamycin treatment in anti-tumor therapy. In this case, rapamycin
blocks the assembly of mTORC2, which in conjuction with phosphoinositide-dependent
protein kinase 1 (PDK1) phosphorylates AKT (Sarbassov et al., 2006). However, the
mechanism behind why certain cells display this secondary sensitivity to rapamycin and
predictive biomarkers for this effect are not known. Regardless, this finding brings up
the possibility that the successful clinical responses to rapamycin may reflect the dual
inhibition of mTORC1 and mTORC2.
Rapamycin in the treatment of TSC
While the role of mTOR in cancer remains murky, the role of mTORC 1 is much
clearer in the case of patients with Tuberous Sclerosis Complex (TSC). TSC is an
autosomal dominant genetic disease with an incidence of 1/6000 at birth, and is
characterized by benign tumors (hamartomas and hamartias) involving multiple organ
systems (Kwiatkowski and Manning, 2005). While TSC as a syndrome was described
over a century ago, the relatively recent discovery that patients with TSC have
inactivating mutations in either TSC1 or TSC2 was a major step forward towards
elucidating the mechanism of the disease. There are several hamartoma syndromes that
share pathological features with TSC, including Cowden Disease, Peutz-Jeghers
Syndrome, neurofibromatosis and Birt-Hogg-Dube Syndrome. Like TSC1 and TSC2, the
tumor suppressor genes linked to these diseases (PTEN, LKB1, NF1 and FLCN
respectively) encode proteins that restrict mTORC1 signaling (Corradetti et al., 2004;
Shaw et al., 2004). In addition to harmatomas, patients with TSC also develop
angiomyolipomas (AMLs) and lymphangioleiomyomatosis (LAM). Unlike harmatomas,
both lesions can be highly proliferative with AMLs consisting primarily of smooth
muscle cells, fibrous tissue, adipose tissue, and abnormally formed vascular channels
(Gomez, 1999). While the prognosis of patients with AMLs can be encouraging given
the ability of recurring surgeries to manage the lesions, the prognosis of patients with
LAM can be grim with often relentless disease progression. LAM is an infiltrative,
proliferative lung lesion composed of aberrant smooth muscle and epithelioid cells with
cyst formation and destruction of normal airways (Moss et al., 2001).
The results from clinical trials treating TSC patients with rapamycin are variable.
One trial, five of five TSC patients had significant regression of cerebral astrocytomas
using an oral rapamycin analogue (Franz et al., 2006). However, rapamycin treatment of
18 TSC patients with renal AMLs only reduced AML volume by a modest 30%, with 17
of 18 patients experiencing tumor regrowth upon termination of the trial. Whether this
reduction in AML volume is sufficient to reduce secondary complications and related
organ failure is unclear (Bissler et al., 2008). Two independent rapamycin therapy trials
of patients with LAM return contradictory results. One trial found a significant
improvement in lung function in 70% of patients (Bissler et al., 2008), whereas another
independent trial with LAM patients found mild to moderate deterioration of lung
function upon rapamycin treatment (Davies et al., 2008). These conflicting results
underscores the need to develop accurate in vivo models of TSC in order to learn more
about these independent lesions and the roles mTORC1 hyperactivation play in their
pathology.
mTORC1 in growth and metabolism
With the ability to respond to numerous growth programs and to sense nutrients
and energy, it is expected that mTORC1 plays a fundamental role in cellular, organ and
organismal metabolism and growth. In multi-cellular organisms, energy is stored
asymmetrically in different tissues, which in turn have different metabolic needs. As a
result, mTORC1 will most likely serve unique functions in each tissue; moreover,
perturbations of mTORC1 in one tissue could have non-autonomous metabolic
consequences. Fortunately, regulation of growth in mammals and insects is well
conserved. The TOR field has benefited greatly from genetic analysis of the pathway in
flies to inform parallel experiments in mice. Both use insulin and insulin-like growth
factors to control rates of cell growth, nutrient use, cell size and body size. Furthermore,
steroid hormone-nuclear receptor signaling regulates transitions between life-stages and
growth in both. Below is a review of insect and animal models of mTORC1 mutants and
their resulting growth and metabolic phenotypes.
TOR and Drosophila
In Drosophila, organismal growth occurs during larval development and is
affected by nutrition, temperature and the genetic program. For example, withdrawal of
protein during larval development results in smaller flies (Britton and Edgar, 1998).
Larval growth is regulated by an endocrine system based on humoral peptides similar to
glucagon (adipokinetic hormone) and insulin (insulin-like peptides (ILPs)) that allows the
insect to coordinate rates of cell growth with changes in diet. Similar to mammals, ILPs
bind to membrane bound tyrosine kinase receptors and trigger PI3K /AKT/dTOR
activation, which, together, compose the insulin/insulin-like growth factor signaling (IIS)
system. In the adult fly, in addition to promoting glucose transport and nutrient storage,
the IIS system affects feeding behavior, lifespan and reproduction.
Genetic experiments have demonstrated that the IIS system is not only essential
for cell and organ growth, but also is sufficient to autonomously increase the growth rate
of essentially any cell type (Britton et al., 2002). For example, flies lacking the function
of Chico (homologue to IRS-1) are smaller due to decreased cell size and number (Bohni
et al., 1999); conversely, flies lacking PTEN have larger cells and enhanced growth
(Goberdhan et al., 1999). This pathway is sensitive to nutrient state; starvation represses
expression of several ILPs, depletes the second messenger PIP3 and inhibits the activity
of the TOR target S6K (Oldham et al., 2000). During larval development, genetically
activating IIS or dTOR signaling by overexpression of p110 or Rheb can bypass the
known cellular effects of starvation, including the arrest of cell growth and DNA
replication in the larval-specific tissues (Saucedo et al., 2003), and the induction of
autophagy in the fat body (Scott et al., 2004). These observations indicate that IIS and
dTOR activity are suppressed in the larval-specific tissues by starvation, and that this
systemically mediates a set of cellular responses that allow insect larvae to cope with
fluctuating nutritional conditions.
Nonautonomous dTOR signaling
In flies and mammals, TOR responds to PI3K/AKT activation and amino acid
input. However, withdrawal of amino acids does not downregulate PI3K or AKT
activities in culture, suggesting that this pathway does not directly respond to nutrient
shortage (Hara et al., 2002). Therefore, the question remains of how nutrient availability
is linked to humoral and cellular mechanisms that modulate PI3K/AKT activity. To
address this question, a recent study tested whether a specific organ, the larval fat body
(FB), can function as a nutrient sensor and induce nonautonomous modulation of
insulin/IGF growth signaling in peripheral tissues in response to changes in nutrient
levels. Analagous to a combination of the vertebrate liver and adipose tissue, the FB
during larval stages accumulates stores of proteins, lipids, and carbohydrate, which can
then be remobilized to compensate for transitory nutrient shortages. In addition to its
storage function, the FB possesses endocrine activity (Britton and Edgar, 1998).
Colombani et al. found that downregulation of an amino-acid transporter
(slimfast) in just the fat body reduced the size of the FB and induced a general reduction
in the rate of larval growth. The reduction in larval growth correlated to reduced PI3K
signaling in peripheral tissues. This effect is specific to the FB, for inhibition of this
transporter in other tissues of the fly did not exert this non-autonomous effect
(Colombani et al., 2003). Furthermore, inhibition of PI3K activity, which reduces the
size of the FB, was not sufficient to phenocopy this result. Importantly, inhibition of
dTOR signaling in just the FB by either expression of a dominant negative TOR allele, or
overexpression of dTSC1 or dTSC2 did phenocopy the developmental growth reduction
of the larvae seen in the slimfast mutant. To confirm that the phenotype of the slimfast
mutant was due to dTOR inhibition, they found that overexpression of dS6K partially
rescued the slimfast mutant phenotype. These data indicate that dTOR in the FB senses
amino acid levels and can communicate this nutrient signal to the rest of the body by
regulating the endocrine function of the FB. This is the strongest evidence to date of a
non-autonomous role for TOR in the regulation of organismal growth, although whether
this role is conserved in mammals has yet to be determined.
The discovery of new downstream effects of TOR signaling raises the question of
which TOR substrate mediates these various downstream pathways. Elegant genetic
studies in yeast, flies and mice have allowed researchers to conclude that S6K and 4E-
BP1 do not mediate all of the growth-promoting actions of TOR and that there must be
additional substrates. For example, whereas homozygote deletion of dTOR in flies
results in delayed larval growth with eventual growth arrest at 24% of the mass of wild-
type controls, overexpression of dS6K on a dTOR null background only partially rescues
larval growth to the pupal stage (Zhang et al., 2000). Consistent with this result, the
reduction in growth in dS6K mutant flies is significantly less than in dTOR mutants
(Montagne et al., 1999). Taken with the observation that flies lacking d4E-BP have no
cell growth changes (Junger et al., 2003), these results raise the distinct possibility that
TOR probably has other downstream effectors. Genetic screens in yeast and flies have
already begun to uncover new candidates, and further research is needed to establish
these new proteins in the TOR signaling network.
mTOR in mice
In mammals, the insulin/IGF-1 and PI3K signaling networks are involved in
numerous processes ranging from embryogenesis, postnatal growth, the immune response
and aging. As such, derangements in these signaling pathways can result in multiple
pathologies including obesity, diabetes, the metabolic syndrome, atherosclerosis and
cancer. With the discovery of mTOR and its placement downstream of insulin and PI3K
signaling, many researchers have re-examined insulin and PI3K dependent phenotypes in
mice and studied the role of mTOR in the manifestation of these phenotypes. In addition,
the ability of mTOR to sense nutrients directly positions the kinase to regulate numerous
physiological conditions that are sensitive to nutrient fluctuations. Given the wide
breadth of biology that could be affected by mTOR activity, the need to study the role of
mTOR signaling in the intact animal is pressing. However, much of the data gleaned
from such studies is correlative, for genetic proof is difficult to attain given that many of
the germ-line deletions of mTOR components are embryonic lethal (Guertin et al., 2006).
Furthermore, genetic studies in mice are complicated due to the presence of multiple
isoforms for many of the mTOR components that may be able to compensate for deletion
of one isoform. As a result, the generation of conditional knockout mice for the various
mTOR signaling components provides a valuable tool for the study of temporal and
spatial mTORC1 signaling in the postnatal animal. Below I discuss both correlative
evidence of mTORC1 signaling in physiological conditions related to growth and
metabolism and the data gained from both germ-line and conditional knockout studies of
mTORC1 signaling components.
The role of mTORC1 in embryonic development
A low nutrient environment during prenatal development can cause profound
developmental and postnatal growth defects. Nutrient deprivation early in development
can lead to preferential nutrient consumption by the brain at the expense of other tissues
resulting in disproportionality of the fetus. Restriction of nutrients later in development
elicits alternations to fetal development such as decreased pancreative beta-cell mass and
decreased newborn size (Schwitzgebel et al., 2009). As expected, mTOR is essential to
development; deletion of mTOR is embryonic lethal at or around implantation (Gangloff
et al., 2004). Explanted mTOR null blastocysts appear normal, but the inner cell mass
(ICM) and trophoblast cells failed to expand in culture. However, given that mTOR is
contained in at least two distinct complexes, each with different downstream effectors, it
is difficult to interpret which branch is responsible for the implantation defect and early
embryonic lethality. To test the role of mTORC1 specifically in embryogenesis, Raptor,
a necessary component of mTORC 1, was deleted. Although they are able to implant,
Raptor null embryos fail to expand and differentiate, dying shortly afterwards.
Consistent with this result, the ICM and trophoblast cells from explanted Raptor null
embryos expand only briefly before detaching and dying (Guertin et al., 2006).
Surprisingly, mLST8 null embryos do not phenocopy the mTOR or Raptor null embryo.
mLST8 was later found to not be required for the actions of mTORC1 in vivo (Guertin et
al., 2006); it is required, however, for in vivo mTORC2 function (Guertin et al., 2006).
S6K1 knockout mice are viable
While studies with mTOR and Raptor knockouts confirm the essential role for
these proteins in embryogenesis, mice null for the mTORC1 substrates S6K and 4E-BP
are viable, thus allowing for the study of the role of mTORC1 signaling in the adult
animal. In 1998, the Kozma and Thomas lab published a report describing the S6K1
knockout mouse (Shima et al., 1998). In keeping with the role of mTORC1 in cell size,
S6K1 null embryos are smaller in utero due to a decrease in cell size, but there are no
alterations in cell proliferation. As a result, null mice are born ~20% smaller than their
wild-type littermates. Mutant mice continue grow at a slower pace through the first 5-6
weeks of postnatal development. At 11 weeks, mutant mice continue to about 15%
smaller than wild-type controls (Shima et al., 1998), with all organs proportional to body
size. This growth phenotype confirms that mTORC1 plays a major role in both prenatal
and postnatal growth. Whether the control of growth is cell autonomous, non-
autonomous, or a combination of the two has yet to be determined.
Given the role of S6K in regulation protein translation and ribosome biogenesis, it
was quite a surprise when the researchers found no apparent defect in translation of
mRNAs modified by a 5' terminal oligopyrimidine tract (TOP) or in S6 phosphorylation
in S6K1 null mice. This unexpected result led directly to the discovery of a second S6
kinase, S6K2 that can compensate for S6K1 in respect to S6 phosphorylation and 5' TOP
mRNA translation. However, S6K2 did not compensate for the small size phenotype,
implying that the size control exerted by mTORC1 via S6K is through a mechanism
separate from S6 phosphorylation (Shima et al., 1998). S6K2 knockout mice were later
generated and actually were larger in size than control mice, and S6K2 null cells exerted
no proliferation or translational defects. The combined deletion of both S6K1 and S6K2
resulted in perinatal lethality (Pende et al., 2004).
As the S6K1 null mice were further characterized, an aspect of mTORC1
signaling arose which confounds analysis of the pathway in the intact animal. As stated
above, mTORC1 is activated by multiple inputs, such as growth factors, insulin, energy
status, oxygen and nutrients. In a process that is not fully understood, mTORC1
phosphorylation of S6K1 not only mediates growth, but also limits growth factor
signaling via a negative feedback loop. As a result, a mutation that activates or
inactivates mTORC1 activity towards S6K can push insulin signaling in the opposite
direction. For example, the loss of S6K1 abrogates the negative feedback loop to insulin
signaling, thus making tissues hypersensitive to insulin input. This aspect of mTORC1
signaling is evident in the fact that the S6K1 null mice are not only hypoinsulinemic due
to decreased P-cell mass, but are also hypersensitive to insulin signaling (Pende et al.,
2000). Moreover, p-cells in mutant mice are disproportionately smaller than other
pancreatic endocrine cells as well as other cells in peripheral tissues. The decrease in
surface area of the 3-cells decreases insulin secretory potential. While mTORC1
regulates P-cell size, it does not seem to impinge upon the ability of p-cells to sense
glucose and secrete insulin accordingly (Pende et al., 2000). Whether the decrease in
growth rate in S6K1 null mice results from decreased circulating insulin, decreased
mTORC1 signaling in tissues, or a combination of the two remains to be determined.
This combination of decreased mTORC1 signaling, decreased insulin levels and
hypersensitivity to insulin allows S6K1 null mice to also be resistant to diet and age-
induced obesity (Um et al., 2004). At the termination of postnatal growth, whole-body
metabolism shifts from a growth-promoting paradigm to an energy storage mode where
excess carbohydrates are stored as glycogen and excess fatty acids are stored as
triglycerides in adipose tissue. Unlike their wild-type counterparts, adult S6K1 null mice
did not exhibit fat storage as they aged. Dissection of mutant mice revealed marked
reduction in both white and brown adipose tissue. Loss of fat is normally associated with
the starvation response; however, S6K1 null mice did not eat less, nor did they exhibit
other hallmarks of a starvation response, lowered plasma glucose and increased plasma
ketone levels. Fat accumulation is dependent on a balance between insulin-stimulated
triglyceride accumulation and epinephrine/glucagon induced lipolysis. Compared to age-
matched controls, Um et al. found a five-fold increase in the rate of fat lipolysis as well
as an increase in metabolic rate as measured by oxygen consumption. This result was
independent of epinephrine action. One would expect that increased lipolysis would then
translate into increased presence of free fatty acids in the blood. However, S6K1 null
mice exhibited comparable levels of plasma free fatty acids and triglycerides to wild-type
controls, thus suggesting increased oxidation of fatty acids in mutant animals. Loss of
S6K1 converted white adipose tissue into an energy-consuming tissue by increasing
mitochondria number and expression of uncoupling protein 1 (UCP1), carnitine
palmitoyltransferase 1 (Cptl) and peroxisome proliferator-activated receptor gamma
coactivator 1 (PGC1 oc). This change in gene expression also occurred in S6K1 deficient
skeletal muscle leading to marked increase in fatty-acid 13-oxidation. The increase in
oxidative capacity of S6K1 deficient skeletal muscle and white adipose tissue allows
mutant mice to resist age and diet-induced obesity (Um et al., 2004).
The role of 4EBPs in mice
This defect in fat accumulation found in S6K1 null mice is reversed in mice
deficient for the other well-characterized mTORC1 substrate 4EBP. In mammals, there
are three 4EBPs, and phosphorylation by mTORC1 results in decreased binding with and
therefore activation of eukaryotic translation initiation factor 4F. As a result, constitutive
activation of eIF4E by deletion of one of multiple 4EBPs mimics a gain of function
mutation in regards to mTORC1 signaling. Mice have been generated with either
deletion of 4EBP1 alone or in combination with deletion of 4EBP2 (Blackshear et al.,
1997; Le Bacquer et al., 2007). Mice lacking 4EBP1 have no obvious abnormalities,
possibly indicating compensation by the other 4EBPs. Mutant mice are not larger at
birth, develop normally, and have no change in appetite or in lifespan (Tsukiyama-
Kohara et al., 2001). However, despite normal plasma insulin levels and presence of
glucose transporters, mice are hypoglycemic. As mutant mice developed into adults,
both males and females were found to weigh less than age-matched wild-type mice. This
difference in weight was not due to changes in organ size, but rather because of a
reduction white adipose tissue weight (Tsukiyama-Kohara et al., 2001). While both
males and female displayed this phenotype, only males were found to have a decreased
metabolic rate as measured by oxygen consumption and CO 2 respiration. Further
examination of white adipose tissue in 4EBP1 knockout mice revealed a strikingly
similar result found in S6K1 knockout mice: increased levels of PGC1 c and UCP1,
factors converting white adipose tissue into an energy consuming tissue more closely
related to brown fat. Whereas there was a transcriptional change in the S6K1 knockout
mice, the increased amount of these proteins in the 4EBP1 null mice was due to increased
translation (Tsukiyama-Kohara et al., 2001).
These results in white adipose tissue are somewhat paradoxical, for it implies that
mTORC1 activation through its downstream substrates S6K1 and 4EBP1 simultaneously
represses transcription of oxidative genes while also increasing their translation. Whether
these results reflect a true physiological role for mTORC1 is unclear due to the presence
of multiple S6Ks and 4EBPs. To clarify the role of 4EBPs in white adipose tissue, the
Sonenberg lab created mice lacking both 4EBP1 and 4EBP2 in the entire body (Le
Bacquer et al., 2007). Again, mice were viable, and developed normally, but in contrast
to the single 4EBP1 knockout mouse, adult double KO mice gained -30% more weight
under normally fed conditions over the course of 16 weeks (Le Bacquer et al., 2007).
This weight gain was primarily a result of increased adipose accumulation. The increase
in fat was accompanied by a rise in plasma insulin and cholesterol levels, thus
establishing the 4EBP1/2 double KO mouse as a model for the development of obesity.
Double KO mice challenged with a high fat diet also gained more weight than control
mice under the same diet. The gain in weight was due again to increased presence of fat
as well as a greater accumulation of triglycerides in the liver. The increased deposition of
fat was due to decreased lipolysis and increased re-esterification of free fatty acids (Le
Bacquer et al., 2007). Repression of 4EBP1 and 2 also leads to insulin resistance. Loss
of these mTORC1 substrates led to increased phosphorylation of S6K1 by mTORC1,
indicating that the 4EBPs and S6Ks compete for catalytic sites in mTORC1. The
increased phosphorylation of S6K in 4EBP1/2 null tissues then suppressed insulin
signaling through the negative feedback loop discussed earlier. The observations made
with these mice mutant for mTORC1 substrates reveal important roles for mTORC1 in
key metabolic tissues, and underscore the physiological importance of the negative
feedback loop between S6K and insulin and growth factor signaling. However, given the
pleiotropic consequence of manipulating fat stores and insulin sensitivity, further
clarification of the physiological roles of mTORC1 will benefit from tissue-specific
deletions.
Tissue specific mTORC1 mouse mutants
Tissue-specific genetic mutations in the mTORC1 signaling pathway allow for
analysis of tissue-specific roles for mTORC1 as well as possible non-autonomous roles
for the signaling pathway. Given the phenotype of S6K1 null P-cells, researchers have
examined the consequence of manipulating mTORC1 specifically in the p-cells.
Deletion of TSC2 specifically in the p-cells of pancreatic islets result in increased P-cell
size and an increase in proliferation. Accordingly, circulating levels of insulin are higher,
and consequently blood glucose levels are lower (Rachdi et al., 2008). However, mutant
mice exhibit normal body weight and postnatal growth compared to wild-type controls,
indicating that such elevated insulin levels in the mutant animals were unable to augment
postnatal growth. The mice did possess improved glucose tolerance due, presumably, to
increased insulin secretion upon glucose injection (Rachdi et al., 2008). However, the
authors were unable to determine whether the mechanism of improved glucose tolerance
was only due to increased insulin secretion and not to non-autonomous effects of
mTORC1 hyperactive signaling in the 1-cells. Although, constitutive mTORC1
signaling led to a sustained suppression of PI3K signaling via the negative feedback loop,
there was no deleterious effect within the p-cell arising from decreased PI3K signaling.
Indeed, the truly surprising result from these mice was the non-oncogenic increase in 13-
cell proliferation. Given that patients suffering from any form of diabetes could benefit
from increased capacity to secrete insulin, the knowledge of a pathway that can increase
3-cell number and size without forming a tumor is quite promising.
As mentioned above, both the S6K1 and 4EBP mutant mice exhibited significant
changes in fat and muscle physiology. Indeed, a role for mTORC1 in fat cell physiology
was first suggested by results showing that rapamycin was required for differentiation
and maintenance of adipocytes in culture (Bell et al., 2000). Moreover, mouse models
for obesity have found increased mTORC1 signaling in white adipose tissue. Such
increased mTORC1 signaling led to sustained suppression of insulin signaling and
resulted in insulin resistance within the fat (Zheng et al., 2009). To study mTORC1 in
vivo, a white adipose tissue specific knockout of Raptor, an essential component of
mTORC1, was engineered (Polak et al., 2008). Fat-specific Raptor knockout confirms
many of the S6K1 null phenotypes. The fat-specific Raptor null mice are lean and are
resistant to diet-induced obesity. Loss of raptor led to decreased adipocyte size and
number. Similar to the S6K1 knockout mouse, the decrease in fat storage upon loss of
Raptor was due to increased oxidative metabolism within the white adipose tissue driven
by increased expression of UCP1 (Polak et al., 2008). Despite losing Raptor only in
white adipose tissue, there were significant changes to whole body metabolism. Mutant
mice had lower circulating levels of insulin, but were more insulin sensitive than wild-
type controls resulting in lowered blood glucose and cholesterol levels (Polak et al.,
2008). This is surprising, for insulin sensitivity, as measured by glucose tolerance test, is
primarily a function of glucose clearance by the muscle and the liver. The authors,
perplexed by this change in whole body metabolism, examined insulin-stimulated AKT
phosphorylation in peripheral tissues. Comparing control and mutant mice on normal
chow, they found that insulin injection stimulated AKT phosphorylation equally in white
adipose tissue and liver, but led to higher levels of phospho-AKT in the muscle of mutant
animals (Polak et al., 2008). Hypersensitivity to insulin in the muscle would explain the
improved glucose tolerance in the fat-specific Raptor knockout mice. However, it
remains unclear how loss of mTORC1 signaling in the fat leads to increased insulin
sensitivity in the muscle. Nonetheless, this result may indicate a non-autonomous role
for mTORC1 signaling within the fat similar to results found in Drosophila (Colombani
et al., 2003). Loss of Raptor in the fat also changed whole body metabolism in response
to a high-fat diet. As expected in the Raptor mutant mice, fat deposition was countered
by increased oxidative capacity (Polak et al., 2008). Moreover, Raptor mutant mice, as
with whole body S6K1 KO mice, continued to be more insulin sensitive under a high fat
diet (Polak et al., 2008). Confirming studies performed in obese mice, Polak et al. found
hyper-phosphorylation of S6K and decreased AKT phosphorylation in the fat of control
mice under a high fat diet due to the negative feedback loop between S6K1 and IRS1.
Loss of Raptor in white adipose tissue eliminated the negative feedback loop, and as a
result, high-fat diet did not lead to hyper-phosphorylation of S6K1 or to decreased AKT
phosphorylation. This could partly explain the increased insulin sensitivity in fat-specific
Raptor null mice under a high-fat diet. In summary, nutrient sensitive mTORC is
required for the important energy storage functions of white adipose tissue; loss of
mTORC1 function engenders a brown fat-like phenotype with increased UCP1
expression and fatty acid oxidation. Loss of mTORC1 signaling in white adipose tissue
leads to increased insulin sensitivity in muscle and prevents onset of insulin resistance
within the adipose tissue on a high-fat diet.
mTORC1 and aging
As more and more studies of mTORC1 within the intact animal are published, a
common theme begins to emerge regarding the physiological role for mTORC1:
regulation of oxidative metabolism. Loss of mTORC1 function in fat results in increased
oxidative capacity due to changes in oxidative gene expression and mitochondria number.
Conversely, gain of mTORC1 function due to deletion of 4EBP1 and 2 leads to decreased
fatty acid oxidation and sensitivity to diet-induced obesity. In contrast to loss of Raptor
in white adipose tissue, loss of Raptor in muscle shows the opposite phenotype: a
decrease in oxidative capacity and mitochondrial gene expression (Bentzinger et al.,
2008). This latter result is similar to a report where rapamycin treatment or Raptor
knockdown in muscle cells and mouse embryonic fibroblasts (MEFs) leads to decreased
oxygen consumption and mitochondrial gene expression (Cunningham et al., 2007).
Taken together, these results suggest that mTORC 1 controls oxidative metabolism and
mitochondrial respiration either positively or negatively depending on tissue. Much more
work is needed, especially examining mTORC1 function in specific tissues. Given the
dramatic metabolic changes caused by manipulation of mTORC1 in fat, muscle and islet
cells, it will be interesting to see how mTORC1 signaling impinges upon metabolism of
the liver.
Oxidative metabolism and mitochondrial metabolism are important in the
adaptive metabolic response to fasting and caloric restriction (CR). Increased
mitochondrial activity and number is also at the center of the mechanism by which CR
extends lifespan in multiple organisms (Guarente, 2008). CR also inhibits TOR signaling
in multiple organisms and has been shown to extend lifespan in yeast, flies, worms and
mice (Kaeberlein et al., 2005; Selman et al., 2009; Vellai et al., 2003). Increased
mitochondrial respiration in yeast and mammals is correlated with increased sirtuin levels
and activity (Lin et al., 2004). The anti-aging proteins, sirtuins, play a major role in the
control of lifespan in response to CR. SIRT1 has also been shown to deacetylate PGC-
1 oc, thereby increasing its ability to stimulate transcription of nuclear genes encoding
mitochondrial proteins as well as mitochondria number (Gerhart-Hines et al., 2007).
As described above, mTORC1 also regulates the levels and activity of PGC-1 oc.
Whether this marks a convergence point between SIRT and mTORC1 in regulating
energy balance and mitochondrial respiration has yet to be determined. However, recent
reports have established mTORC1 as an important mediator in extending lifespan in
response to CR. The S6K1 full body knockout mouse lives longer and is resistant to age-
related pathologies such as bone, immune and motor dysfunction as well as loss of
insulin sensitivity (Selman et al., 2009). Interestingly, only female mutant mice exhibited
this longevity phenotype, although both males and females had improved metabolic
parameters (Selman et al., 2009). Gene expression profiles of liver from fed mutant
animals were similar to profiles from livers of wild-type mice subjected to long-term CR.
Both profiles exhibited expression changes for genes involved in PPARy, PGC-l oc and
SIRT1 signaling (Selman et al., 2009). This result is a genetic confirmation of another
recent report describing the ability of oral rapamycin treatment to extend lifespan in both
male and female mice (Harrison et al., 2009).
Conclusion
In summary, the mTOR signaling network coordinates numerous cellular growth
processes with nutrients, energy, oxygen and humoral growth factors. The mTOR field
has been driven by advances made in yeast, fly and worm genetics as well as genetic and
biochemical studies performed mammalian cells. The last ten years has also seen a
plethora of mammalian in vivo studies illuminating important autonomous and non-
autonomous physiological roles for mTORC1. The challenge now is to delve deeper into
mechanistic studies to understand how tissue-specific proteins impinge upon mTORC1
function. Recent exciting studies have outlined how pharmaceutical modulation of
mTORC1 can have profound impacts on tumor therapy, metabolic disorders and even
aging. However, many of these same studies have also demonstrated very puzzling
results that underscore how much more there is to learn about mTORC1 biology.
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Summary
In fasted animals the liver performs numerous functions that maintain whole-body
nutrient homeostasis, including the production of ketone bodies for peripheral tissues to
use as energy sources. Aged rodents have a liver autonomous defect in ketogenesis that
correlates with a reduction in the activity of PPARa, a master transcriptional regulator of
ketogenic genes. Here, we show that the multi-component mTORC1 kinase controls
ketogenesis in response to fasting as well as aging. Liver-specific loss of TSC1, an
mTORC 1 inhibitor, leads to a fasting-resistant increase in liver size and a pronounced
defect in fasting-induced ketone production, while the loss of raptor, an essential
mTORC1 component, has the opposite effects. Neither a synthetic PPARa ligand nor
PPARa overexpression can induce ketone production or ketogenenic gene expression in
livers or cultured cells lacking TSC1. mTORC1 inhibits ketogenesis by preventing the
fasting-induced nuclear-exit of NCoR1, a negative regulator of PPAR. The deletion of
TSC1 does not further decrease ketone production beyond that reduced by aging while,
the loss of raptor is sufficient to correct the aging-induced defects in ketogenesis and
expression of PPARac target genes. Thus, these findings show that mTORC1 is an
important modulator of hepatic ketogenesis and PPARa function and support a role for
mTORC1 activity in promoting the aging of the liver.
Introduction
In multi-cellular organisms, evolution has developed a complex interplay between
energy consumption, utilization and storage to provide maximal survival to the organism
in the face of an uncertain food supply and intermittent fasting. This check and balance
system can lead to profound effects such as inhibition of prenatal and postnatal growth
when nutrients are limited. Conversely, in the modern era, when food is both plentiful
and varied, this same system can lead to pathologies such as obesity, diabetes and
atherosclerosis. In addition, the reduced metabolic fitness of many organisms with aging
indicates that aging changes the efficacy and sensitivity of many metabolic pathways. As
such, elucidating the molecular mechanisms behind these metabolic pathways is
important for understanding their regulation of organ and organismal growth, their
response to fluctuations in nutrient levels, and pathologies they may produce in response
to an overabundance of food and aging.
In mammals, the liver plays a key role in nutrient-regulated organ and organismal
growth and in buffering nutrient level due to feeding and fasting cycles. In response to
growth hormone (GH), the liver secretes multiple insulin growth factors (IGFs) of which
many are required for prenatal and/or postnatal growth (Lupu et al., 2001). Circulating
levels of both GH and IGF-1 are reduced under dietary restriction (Shimokawa et al.,
2008). In addition to its endocrine roles, the liver is able to store or liberate glucose, and
synthesize lipids and cholesterol for transport to peripheral tissues. In periods of
extended fasting or in response to dietary restriction, the liver synthesizes glucose and
ketone bodies from fatty acids and amino acids liberated from adipose stores and muscle
respectively. These liver functions are governed by an interplay between hormones,
transcription factors, and energy substrates, allowing rapid responses to changes in
metabolic need (Herzig et al., 2003).
Even the size of the liver is tied to nutrient status. In the rat, a 48-hour fast
decreases liver size by 44% as a function primarily of hepatocyte size (Fenn, 1939). The
liver also possesses remarkable regenerative capacity, metabolizes large number of drugs
and synthesizes bile acids needed for absorption of dietary fats. Interestingly, aging leads
to a perturbation in numerous liver functions including regenerative capacity
(Timchenko, 2009), drug metabolism (Durnas et al., 1990), bile synthesis from
cholesterol (Stahlberg et al., 1991), protein synthesis (Ward and Richardson, 1991), and
ketone synthesis (Okuda et al., 1987). Given the myriad of metabolic and growth-related
functions carried out by the liver, it is an enormous challenge to decipher all of the
various inputs that stimulate, suppress or in general modulate these processes whether
they be hormones, growth factors, chemicals or nutrients.
The mTOR complex 1 (mTORC1) is a multi-component kinase that responds to
stimuli such as amino acids, growth factors, insulin, stress and hypoxia and regulates cell
growth via modifying protein translation, ribosome biogenesis, and autophagy. When
active, mTORC1 also suppresses insulin signaling at the level of insulin receptor
substrate in a classic negative feedback loop (Harrington et al., 2005). Given its ability to
regulate cell size in response to nutrients, growth factors, and insulin we hypothesized
that mTORC1 would have an impact on regulating liver size in response to feeding and
fasting. What is less clear is what liver functions are regulated by mTORC1. Given that
mTORC1 is activated by insulin signaling via PI3K and AKT, initial research studied
whether the mTORC1 mediated any insulin-dependent liver functions.
Insulin plays an important role in controlling glucose and lipid homeostasis by
affecting multiple organs including muscle, fat and liver. Impairment of insulin signaling
pathway plays a key role in the development of type-2 diabetes and the metabolic
syndrome. Decreased plasma insulin levels also correlate with lifespan extending caloric
restriction regimens. In the liver, insulin stimulates glycogen synthesis, glycolysis and
lipogenesis, while suppressing gluconeogenesis and fatty-acid oxidation. Insulin
signaling can affect metabolic pathways through signal transduction pathways and by
changing patterns of gene expression and mRNA translation. Furthermore, the liver
serves to clear insulin via receptor-mediated endocytosis. (Terris et al., 1979).
The physiological role of mTORC1 has been analyzed by full body knockouts of
mTORC1 substrates and through the use of the mTORC1 inhibitor rapamycin. Mutant
mice null for the mTORC1 substrate S6K1 in all tissues are smaller, hypoinsulinemic, are
resistant to diet-induced obesity, and females experience extended lifespan (Selman et al.,
2009; Um et al., 2004). Conversely, mice deficient for 4E-BP1 and 4E-BP2, substrates
of mTORC 1 where phosphorylation leads to inactivation, are sensitive to diet-induced
obesity, have increased adipose tissue, and are insulin resistant (Le Bacquer et al., 2007).
While the phenotypes of these mutant mice are very compelling, it is difficult to ascertain
the individual contribution of mTORC1 in separate tissues to the phenotypes observed.
More recently, tissue specific mutations in mTORC 1 signaling have been generated in
astrocytes (Uhlmann et al., 2002), skeletal muscle (Bentzinger et al., 2008), the beta-cells
of pancreatic islets (Rachdi et al., 2008), and fat (Polak et al., 2008), but not liver.
Analysis of mTORC1 signaling kinetics and activity in the liver of obese rats
found higher basal activity and accelerated response to insulin, thereby indicating that
metabolic disorders such as obesity are correlated with aberrant hepatic mTORC1
signaling. The role of mTORC1 in insulin mediated liver function was probed through
the use of the mTORC1 inhibitor rapamycin. Using isolated rat hepatocytes, researchers
found that rapamycin had no effect on insulin stimulated transcription of gluconeogenic
genes such as phosphoenolpyruvate carboxykinase (PEPCK) (Liao et al., 1998), or on
insulin stimulated glycogen synthesis (Peak et al., 1998). However, recent work from our
lab and others has demonstrated that rapamycin does not truly phenocopy loss of
mTORC1 function (Thoreen et al., 2009), thereby emphasizing the need to genetically
perturb the mTORC1 pathway to truly study its function in hepatic physiology. Here we
describe two mouse mutants that allow dissection of both hepatic gain of function and
loss of funtion of mTORC 1 through the use of conditional alleles. Our analysis confirms
that mTORC1 does not play a major rule in regulating hepatic glucose metabolism
independent from modulation of the insulin/PI3K/AKT pathway via negative feedback.
However, we do uncover a novel role for mTORC1 in the regulation of hepatic fatty acid
oxidation and ketone synthesis in response to fasting and aging.
Results
Hepatic mTORC1 signaling responds to feeding, and regulates liver size.
We first established that hepatic mTORC 1 is fasting and refeeding sensitive.
Upon activation, mTORC1 phosphorylates its downstream substrate S6 kinase, which in
turn phosphorylates ribosomal protein S6. Mice fasted for 24 hours exhibited low levels
of phosphorylated S6 as determined by immunofluoresence on paraffin-embedded liver
sections and western blot analysis on whole-cell lysates from liver (Figure 1A and IB).
Mice refed with chow displayed an increase in phosphorylated S6 in a time-dependent
manner that is blocked by administration of rapamycin via intra-peritoneal injection 2
hours before refeeding (Figure lA and IB). Given that mTORC1 activity is modulated
by changes in feeding status, we wished to determine which fasting and feeding related
liver functions were regulated by mTORC1 activity. To do so, Tscl conditional
knockout mice were obtained (Uhlmann et al., 2002), and conditional knockout Raptor
mice generated. Retro-orbital injection of high-titer adenovirus expressing Cre
recombinase resulted in loss of Tscl expression specifically in the liver
(LiTsclKO)(Figure IC). Loss of Tscl, an inhibitor of mTORC1 activity, resulted in
constitutive expression of mTORC1 as exhibited by constant levels of phosphorylated S6
in fed, fasted and refed mice (Figure 1D). Raptor conditional knockout mice did not
exhibit sustained loss of Raptor expression upon adenoviral Cre injection (data not
shown), so mice were crossed with those expressing Cre from the liver-specific albumin
promoter (LiRapKO) (Figure 1C). Loss of hepatic Raptor expression led to low levels of
phosphorylated S6 in fed, fasted and refed mice (Figure ID). Long-term fasting in many
mammals induces a profound loss of liver mass due to a decrease in hepatocyte size.
LiTsclKO and LiRapKO mice had larger and smaller livers respectively due to changes
in hepatocyte size and did not lose liver mass upon fasting like their wild-type littermates
(Figure lE). Histological comparison with wild-type liver sections uncovered not only
changes in hepatocyte size in the mutant mice, but also changes in ploidy (Figure 1F).
LiTsc IKO mice possessed larger percentage of hepatocytes with polyploidy or binucleate
nuclei, whereas LiRapKO mice possessed a smaller percentage of such hepatocytes
(Figure 1F). The changes in cell size also correlated with changes in protein content
consistent with the important role mTORC1 plays in protein synthesis (data not shown).
LiTsclKO mice have lower plasma ketones than control mice in response to fasting.
In response to fasting, the liver performs numerous functions to maintain essential
levels of plasma nutrients. In the initial stages of the fasting response, the liver liberates
its carbohydrate stores, and performs gluconeogenesis. As the fasting state progresses,
fat stores are lipolyzed and glycerol and free-fatty acids are released into the blood and
taken up by the liver to be used as building blocks for glucose and ketone production. It
is in the latter stages of a prolonged fast when ketones become increasingly important as
a source of acetyl-CoA for peripheral tissues including the brain. Ketones also serve as a
major fuel source during sustained periods of dietary restriction.
We sought to determine whether hepatic mTORC1 inhibition was necessary for
the execution of the fasting response by the liver. To do so, plasma metabolite levels of
LiTsclKO mice were compared to wild-type mice to determine the consequence of
ectopic mTORC1 activation in the liver during a 48 hour fast. The analysis also included
mice with a liver-specific deletion of the insulin receptor (LIRKO) to control for the
negative feedback loop between the mTORC1 substrate S6K and IRS (Michael et al.,
2000), as well as LiRapKO mice. We collected plasma from fed mice and mice fasted
for 24 and 48 hours and measured numerous factors including glucose, triglycerides, free-
fatty acids (FFA), and ketones (Table 1). In addition, we measured levels of triglycerides
and glycogen in the liver (Table 2). All mutant mice were compared to their respective
wild-type littermates to control for any differences in strain background. Plasma levels of
many metabolites were similar between control and mutant animals. However, we found
that LiTsclKO had significantly decreased levels of plasma ketones in response to
fasting- a phenotype not shared by LIRKO or LiRapKO mice (Table 1 and Figure 2A).
The defect in ketogenesis in LiTsclKO mice is liver autonomous.
In the adult mouse, ketones are produced in the mitochondria of the liver and
kidney from Acetyl-CoA generated primarily by fatty acid oxidation. Given that plasma
levels of FFA were unchanged between wild-type and LiTsclKO mice (Table 1), our first
concern was whether there was a defect in FFA uptake by Tscl deficient livers. To
address this concern, we fasted control and LiTsc lKO mice for 24 hours and injected
mice with sodium octanoate- a medium-chain fatty acid that has been previously shown
to freely diffuse into mitochondria of livers and serve as a ketogenic substrate ((McGarry
and Foster, 1971). Control mice showed a time-dependent increase in plasma ketones
after injection, whereas LiTsclKO mice were unable to generate ketones even when
presented with substrate (Figure IB). Additionally, we performed ex vivo hepatic assays
measuring rate of fatty acid oxidation from radiolabeled oleic acid. Hepatic fatty acid
oxidation was severely blunted in livers lacking Tscl compared to control livers (Figure
IC). Thus, we determined that the dramatic decrease in plasma ketones upon fasting
found in LiTsclKO mice were due to a liver autonomous defect in fatty acid oxidation
and ketone production.
Given that Tscl loss and therefore constitutive activation of mTORC1 inhibited
hepatic ketogenesis, we predicted that loss of Raptor in the liver would lead to a
constitutive ability to make ketones- even in the fed state. However, the sharp rise in
insulin upon refeeding inhibits lipolysis and leads to decreased plasma FFA levels
available to the liver for ketone production. To circumvent the lack of substrate, refed
control and LiRapKO mice were given an injection of sodium octanoate upon refeeding
following a fast. Whereas refed wild-type animals shut down their ketogenic programs
and are unable to produce ketones from injected sodium octanoate, LiRapKO mice were
able to produce ketones in the hours post refeeding (Figure 1D).
TSC1 loss suppresses PPARoc signaling, whereas Raptor loss ectopically activates
PPARoc signaling.
Ketogenesis is a multi-component process that is regulated by hormonal input and
substrate availability. The nuclear transcription factor peroxisome proliferator-activated
receptor-alpha (PPARo) is a necessary component of the ketogenic response. PPARC
senses availability of substrate and transactivates numerous enzymes including those
involved in fatty acid oxidation and ketogenesis. Endogenous ligand for PPARC is
generated from the influx of FFAs into the liver during fasting. Upon ligand binding,
PPARoc is released from a co-repressor complex and binds to co-activators resulting in
transactivation of itself and its targets. PPARo targets include carnitine
palmitoyltransferase la (Cptla), the rate-limiting enzyme for transport of FFAs into the
mitochondria; acyl-Coenzyme A oxidase 1 (AOX), an enzyme that involved in beta-
oxidation of FFAs to generate Acetyl-CoA, and mitochondrial P-hydroxy-3-
methylglutaryl-CoA synthase (HMGCS2) which is the rate limiting step of synthesis of
the ketones acetoacetate and P-hydroxybutyrate from Acetyl-CoA (Hsu et al., 2001). In
addition to ligand-induced activation of PPARcx, numerous papers have reported other
pathways that modulate the PPARoc response to fasting and no precise mechanism has
been established
Given that the livers of LiTsc 1KO mice fail to produce ketones during fasting
even when presented with fatty acid substrate, we examined transcript levels of PPARoc
and many of its targets. Fasting in wild type mice leads to an increase in mRNA levels of
PPARoc and its targets. However, mRNA levels of these same genes did not increase
upon fasting in Tsc 1 deficient livers (Figure 2E). As fasting leads to an increase,
subsequent refeeding leads to a decrease in mRNA expression of these same enzymes,
PPARoc, HMGCS2, and CPTla, within hours. After 48 hours of fasting, LiRapKO mice
exhibit similar transcript levels of these enzymes compared to wild-type controls, but
after 2 hours of refeeding, while wild-type mice show a significant decrease in these
transcript levels, levels remain elevated in LiRapKO livers (Figure 2F).
mTORC1 suppression of PPARoc is dominant to administration of exogenous
PPARc ligand and to overexpression of PPARc in vivo and in vitro
To determine whether the inability of LiTsclKO livers to upregulate PPARc
targets are due to defective ligand production, we treated mutant and wild-type mice with
the synthetic PPARoc agonist WY 14643 for 5 days, and then re-examined their plasma
ketone levels and mRNA levels of ketogenic enzymes upon 48 hour fast. We found that
5-day treatment of the PPARoc agonist lead to an increase in both plasma ketone levels
and transcript levels of all enzymes in wild-type mice. However, agonist treatment failed
to restore plasma ketone and ketogenic transcript levels in LiTsc IKO mice upon fasting
(Figure 3A and 3B). PPARcX and HMGCS2 transcript levels in the intestines of both
control and mutant animals showed a robust increase in response to agonist treatment
confirming its efficacy (Figure 3B). To confirm this result, knockdown of Tscl or Tsc2
was performed in the transformed mouse hepatocyte cell line AML12. To trigger
ketogenesis, cells were placed in a ketogenic media (KM) devoid of insulin and serum,
and containing sodium octanoate and WY 14643. Compared to control GFP knockdown
cells, reduction in Tscl or Tsc2 resulted in a decreased ketone output when placed in KM
(Figure 3C, and data not shown). The ketogenic capability of AML12 cells with reduced
Tscl or Tsc2 levels was restored with rapamycin treatment (Figure 3C, and data not
shown). The degree of knockdown for Tscl and Tsc2 was validated by RT-PCR (Figure
3C). The cell culture results confirm that the defect in ketogenesis by loss of Tsc1 is cell
autonomous and due to modulation of mTORC1.
Fasting leads to an increase in the mRNA of PPARc itself due to PPARx
transactivating its own promoter. Mice with hepatic loss of Tscl fail to upregulate
PPARoc mRNA levels upon fasting. To test whether the reduction in PPARoc levels in
LiTsclKO livers causes the defect in ketogenesis, mutant and control mice were injected
with adenovirus expressing PPARoc. Hepatic overexpression of PPARoc failed to rescue
plasma ketone levels upon fasting in LiTsclKO mice (Figure 3D). This same experiment
was repeated in AML12 cells with stable expression of GFP or Tscl shRNAs. Again, we
find that overexpression of PPARX failed to rescue the defect in ketogenesis in Tscl
knockdown cell lines placed in KM compared to cells in complete media (CM) (Figure
3E). Overexpression of PPARoc was confirmed by RT-PCR (Figure 3D and 3E).
The PPARoc corepressor NCoR1 does not disassociate from PPARo target
promoters upon fasting in livers from LiTsclKO mice.
Given that both overexpression of PPARoc and presence of excess ligand failed to
induce ketogenesis and PPARoc transcriptional activity in Tscl deficient livers and cells,
we next looked at processes that regulate PPARoc at the promoter. In the fed state, a
large multi-component corepressor complex binds to the PPARoc at peroxisome
proliferator response elements (PPREs) of target promoters. Promoter repression is
accomplished by the histone deacetylase activity of the corepressor complex, which
results in a tight chromatin structure. Upon fasting and subsequent ligand binding,
PPARoc undergoes a confirmational change and the corepressor complex is possibly
modified resulting in disassembly of co-repressor proteins and assembly of a series of co-
activator proteins. The co-activator complex activates the promoter through histone
acetylase and methylase activity and also recruits and binds the transcriptional
machinery. Using chromatin immunoprecipitations assays, we measured the degree of
chromatin modification in the promoters of PPARoc, Cptla and HMGCS2. Comparing
promoters from fed (repressed) and fasted (activated) livers, we found no significant
increase in acetylation of PPREs from Tsc 1 null livers in contrast to wild-type controls
(Figure 4C). We next examined the switch from corepressor to coactivator complex
binding to these promoters in the fed to fasted transition. We see the expected transition
from nuclear receptor co-repressor 1 (NCoR1) to coactivator p300 binding at PPREs
from wild-type livers in response to fasting. However, we find constitutive binding of the
corepressor protein NCoR1 at the PPREs of LiTsclKO promoters (Figure 4A and 4B).
This result is consistent with the lack of histone acetylation in PPREs of LiTsclKO
promoters.
Knockdown of NcoRl or inhibition of NCoR1 histone deacetylase activity rescues
the ketogenic defect in Tscl knockdown cells.
Based on the results obtained from the chromatin immunoprecipitation
experiments, we hypothesized that knock down of NCoR1 in Tscl-knockdown cells
should lift the ectopic repression of PPARoc transcription. In KM, TSC1/NCoR1 double
knockdown cells produce equivalent amount of ketones compared to GFP and NCoR1
knockdown cell lines (Figure 4D). As previously noted, cells with Tscl knockdown
alone continued to show a dramatic defect in ketogenesis (Figure 4D). We concluded
that ectopic activation of mTORC1 under fasting conditions led to a defect in NCoR1
disassociation from the promoters of PPARoc target genes. As a result, even in the
presence of ligand and increased PPARoc, the promoters were constitutively silenced due
to the continued histone deacetylase activity of the NCoR1 containing corepressor
complex. Therefore, administration of a pharmaceutical HDAC inhibitor such as
Trichostatin A (TSA) should phenocopy loss of NCoR. Treating either GFP or Tscl
knockdown cells with TSA placed in KM exerted no significant effect on control cells,
but fully rescued the defect in ketone production in Tsc 1 KD cells (Figure 4D).
mTORC1 regulates NCoR1 localization
NCoR1 is a ubiquitous transcriptional repressor and is regulated by multiple
paradigms. NCoR1 represses of NFKB signaling, and TNFoc stimulation lifts this
inhibition by triggering relocalization of NCoR1 out of the nucleus into the cytoplasm
(Espinosa et al., 2002). We tested whether mTORC1 uses this paradigm for regulating
NCoR1 activity. Liver sections from fed and 24 hour fasted LiTsclKO mice were
stained with an antibody to NCoR1 and compared to controls. In control mice, fed
animals show NCoR1 staining in both the cytoplasm and nucleus, but fasting induces a
depletion of NCoR1 staining in the nucleus (Figure 5A). In LiTsclKO mice however,
NCoR1 staining is in the cytoplasm and nucleus under both fed and fasted conditions
(Figure 5B). To confirm this regulation of NCoR1 localization by mTORC1, liver
sections from LiRapKO mice that were fasted for 24 hours or refed for 1 hour were
stained with antibody to NCoR, and compared the staining of liver sections from control
mice under the same conditions. Fasted control mice again showed decreased nuclear
staining for NCoR, while refeeding for 1 hour resulted in increased NCoR1 nuclear
staining (Figure 5C). Liver sections from LiRapKO mice exhibited almost no NCoR1
staining in the nucleus under fasted or refed conditions (Figure 5D). Qualitative
observations were confirmed by image analysis measuring pixel intensity of NCoR1
staining along the diameter of the cell (Figure 5A-D).
Aging induced decrease in ketogenesis is due to mTORC1 repression of PPARoc
signaling
Diminished hepatic ketogenesis and decreased PPARc levels and activity have
been previously found to occur in livers from old rodents. We compared old and young
control mice and confirmed that upon fasting, old mice had lower plasma ketones and
hepatic levels of PPARoc compared to young mice (Figure 6A). When old floxed Tscl
mice were injected with adenovirus-expressing Cre recombinase resulting in loss of Tsc 1,
further dampening of ketogenesis and PPARoc levels was not observed (Figure 6A). This
implies that the aging related decline in PPARoc activity is refractory to any additional
repression caused by constitutive mTORC1 signaling. Accordingly, transcript levels of
PPARoc and its targets Cptla and HMGCS2 are blunted in response to fasting compared
to young controls (Figure 6B). Additional loss of Tscl has no significant additive effect
(Figure 6B). Remarkably, aged LiRapko mice showed no hepatic defects in ketogenesis
or PPARoc activity compared to young LiRapKO mice (Figure 4C and 4D). NCoR1
staining of liver sections from old fed or fasted mice revealed constitutive nuclear
staining raising the possibility that aging may suppress PPARoc via NCoR1 (Figure 6E).
In response to fasting, mice display "foraging behavior," which is an increase in physical
activity. Prolonged fasting eventually leads to onset of torpor- a condition defined by a
drop in body temperature and decreased physical movement. Upon fasting, LiTsclKO
mice experience premature onset of torpor, and do not exhibit increased physical activity
indicative of foraging behavior (Figure 6F and G).
Discussion
In mammals, evolution has developed a metabolism able to survive long periods
of little to no eating. In the fed to fasted transition, there is a gradual shift in whole-body
fuel utilization from a combination of carbohydrates and fat to almost exclusively fat.
For the brain and red blood cells, which are unable to metabolize fat, this shift is
particularly dramatic. Rising ketones levels during fasting supplement endogenously
synthesized glucose for use by peripheral tissues. It is estimated that FFA and their
ketone body derivatives provide ~80% of caloric requirements after 24 hours of fasting in
adult humans (Berk and Stump, 1999). The majority of this conversion from glucose to
fat oxidation for energy occurs in the liver, which plays a central role in the adaptive
response to fasting. We find that the multi-component kinase mTORC 1 regulates fatty
acid oxidation and subsequent conversion into ketone bodies upon fasting.
During a prolonged fast, the body experiences low plasma insulin and high
plasma levels of glucagon, epinephrine and glucocorticoids. This combination of
hormones and chemicals promotes the lipolysis of triglycerides (TGs) from adipose
tissue, thereby increasing the concentration of FFAs in the blood. The liver then takes up
the FFAs where they are either re-esterified into triglycerides and secreted as VLDLs or
oxidized in peroxisomes and mitochondria via beta-oxidation. The majority of fatty acids
are only partially oxidized into acetyl-coenzyme A (acetyl-CoA) which then combines
with itself to form ketone bodies. The ATP generated by beta-oxidation of fatty acids is
used for hepatic gluconeogenesis from substrates such as glycerol, lactate and amino
acids. Therefore, hepatic fatty acid oxidation is required for the metabolic response to
fasting.
Peroxisome proliferator-activated receptors (PPARs) play an important role in
fatty-acid metabolism (Desvergne et al., 1998) by essentially acting as sensors for fatty
acids and their metabolic derivatives (Reddy and Hashimoto, 2001). While there are
three isoforms of PPAR, alpha, gamma, and beta, PPAR alpha (PPARO) is the master
regulator of fatty acid oxidation in the liver (Desvergne and Wahli, 1999). Mice null for
PPARoc are relatively healthy in the fed state, but become hypoglycemic and
hypoketonemic in the fasted state underscoring the requirement of PPARoc in the hepatic
fasting response (Djouadi et al., 1998; Kersten et al., 1999).
PPARoc, irrespective of ligand binding status, remains largely in the nucleus
bound to its target promoters as part of a heterodimer with retinoid x receptor-alpha
(RXRcx) (Guan et al., 2005). In the fed state, these receptors are maintained in a
repressed state by co-repressor proteins such as SMRT and NCoR1 (Dowell et al., 1999;
Guan et al., 2005). These co-repressors bind multiple nuclear receptors and possess or
recruit histone deacetylases or other enzyme activities to tighten chromatin structure thus
inhibiting repressing gene transcription (Guan et al., 2005). As FFAs are taken up by the
liver upon fasting, certain FAs or FA derivatives directly bind to the ligand-binding
domain of PPARx (Forman et al., 1997). Ligand binding contributes towards
dissociation of the corepressor protein complex from PPARo. Disassembly of the
corepressor complex allows for association of coactivator proteins with PPAROC. The
coactivator complex recruits or possesses enzyme activity which acetylates histones, thus
lifting promoter repression and helping recruit the transcriptional machinery (McKenna
and O'Malley, 2002). Just as there are no specific co-repressors for PPARC, the co-
activators for PPARo are also shared among many transcription factors that are involved
in different nuclear receptor signaling pathways (Glass and Rosenfeld, 2000). There may
be upwards of 15 to 30 co-activator proteins that by chromatin remodeling and
scaffolding, provide a molecular bridge that transfer the signal of nuclear receptor
specific gene activation to basal transcription machinery (Roeder, 2005). Some key co-
activators for PPARo include cAMP-response element-binding protein (CREB) binding
protein (CBP) and E1A binding protein 300 (p300), three members of the steroid receptor
coactivator family (SRC- /p 160), and peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1 alpha). The coactivators p300 and CBP possess and recruit
histone acetyl transferase activity that activate the promoters. It is unclear what purpose
PGC-1 alpha serves in promoting transcription of PPARoc targets. While overexpression
of PGC-1 alpha can potentiate PPAR c transcription, loss of PGC-1 alpha has no
deleterious effect (Leone et al., 2005). Given the promiscuity of both the co-repressors
and co-activators that regulate PPARoc transcriptional activity, we are only beginning to
understand how upstream signaling pathways regulate the activity of these corepressor
and coactivator complexes in ways that don't have pleiotropic consequences.
Here we find that hyper-activation of hepatic mTORC1 signaling in LiTsclKO
mice inhibits fasting induced ketogenesis by constitutive repression of PPARc
transcriptional activity. Our findings suggest that this transcriptional repression is
mediated by increased presence of NCoR-1 at the promoter of PPARC and PPARC
transcriptional targets. In contrast to livers of control mice, we find that the onset of
fasting does not lead to disassociation of NCoR1 and increased association of p300 at the
PPARoc response elements of promoters for PPARoc, HMGCS2 and Cptla in LiTsclKO
livers. We functionally verify the defect in this transition in LiTsclKO livers by
detecting no significant increase in histone acetylation at these promoters upon fasting
whereas promoters in wild-type livers show robust histone acetylation upon fasting. The
increased presence of NCoRl at promoters of PPARoc targets also correlates with
increased amount of NCoR1 in the nuclei of fasted hepatocytes from LiTsclKO mice
compared to wild-type mice. We show that either knockdown of NCoR-1 or
pharmaceutical inhibiton of histone deacetylase activity is sufficient to lift this repression
of PPARoc transcriptional activity in hepatocytes with knockdown of Tscl or Tsc2.
Although we were unable to elucidate whether mTORC1 is directly or indirectly
acting on NCoR, it is not surprising that NCoR1 presence at the PPRE is a target of
regulation. In general, the activities of corepressor and coactivator complexes can be
regulated by numerous paradigms. For instance, a polymorphic allele of PPARC found
in the Asian population enhances recruitment of NCoR, and attenuates response to
synthetic PPAR ligands. Silencing NCoR1 or inhibition of HDAC activity restores
transactivation activity of this variant allele of PPARoC in transfected HeLa cells (Liu et
al., 2008). Other signaling pathways modulate NCoR1 mediated repression of
transcription by changing its cellular location. Overexpression of p65-NF-kappa-B
facilitates notch mediated transcription of multiple targets, including Hes-1, by inducing
sequestration of NCoR1 in the cytoplasm through an unknown mechanism. This
translocation abrogates repression by NCoR1 of promoters containing SRF or AP-1 sites
(Espinosa et al., 2002). Finally, work in neural stem cells shows that direct
phosphorylation of NCoR1 by Akt also mediates cellular localization and provides a
paradigm by which cytokines promote differentiation of neural stem cells into astrocytes
via PI3K/Akt signaling (Hermanson et al., 2002).
When first characterizing the defect in ketogenesis in LiTsclKO mice, we
uncovered previous work describing a similar phenotype in aged rodents. Plasma
analysis of ketones, FFAs, and glucagon found a decrease in plasma ketones after a 36
hour fasting period in aged rats compared to young rats, despite higher levels of FFAs
and glucagon. This in vivo analysis was confirmed through experiments using perfused
livers that found that aged livers were not as responsive to glucagon induced ketogenesis
as livers from young rats (Okuda et al., 1987). As we continued our analysis and found a
defect in PPARoc induction and transcriptional activity, we were also intrigued by
previous reports describing an aging related decrease in PPARoc levels and DNA binding
activity in heart (Iemitsu et al., 2002), spleen (Poynter and Daynes, 1998), kidney (Sung
et al., 2004), and liver (Sanguino et al., 2004). Given this compelling data for the affect
of aging on PPARoc in rodents, we examined whether this novel regulation between
mTORC1 and PPARoc is also aging dependent. We first confirmed that aged mice do
exhibit lower plasma ketones upon fasting compared to young controls. This defect
correlates with lowered induction of PPARoc and decreased PPARoc transcriptional
activity. After confirming this link between aging and PPARoc, our results demonstrate
that loss of hepatic Tsc 1 in aged conditional mice did not lead to an additional decrease in
fasting ketone levels. In the reverse experiment, we find that aging does not lead to a
decrease in fasting ketone levels in LiRapKO mice. We confirmed this resistance to
aging by showing no change in PPARoc transcriptional activity between old and young
LiRapKO mice. This is the first mechanistic description of how mTORC1 could regulate
aging in a specific tissue and fits with recent exciting work showing that whole body
inhibition of mTORC1 signaling can extend lifespan and provide resistance to aging
related metabolic defects (Harrison et al., 2009; Selman et al., 2009)
Experimental Procedures
Materials
Conditional Tscl mice were a gift from David Kwiatkowski via Bernardo Sabatini.
Raptor conditional mice were developed with the Rippel Transgenic Mouse facility at
MIT. LIRKO mice were a gift from C. Ronald Kahn. Adenovirus was purchased from
the Gene Transfer Vector Core at the University of Iowa. Antibodies to phospho-
S235/236 S6, phospho-240/244 S6, and total S6 were obtained from Cell Signaling
Technology. Antibodies to NCoR1 were purchased from Upstate Biotechnology and
Santa Cruz Biotechnology, p300 antibodies were also from Santa Cruz Biotechnology,
and all modified histone chip antibodies were from Millipore. Cy3 conjugated secondary
antibody was obtained from Invitrogen. WY 14,643 was purchased from Cayman
chemicals, rapamycin was purchased from LC Labs, and glucagon, epinephrine,
dexamethasone, transferrin, insulin, sodium octanoate, selenium, and oleic acid were
purchased from Sigma. Radiolabeled oleic acid was from Perkin Elmer. Adenovirus
expression PPARoc was purchased from Vector Biolabs. Lentiviral hairpins to TSC1,
TSC2, and NCoR1 were from the The RNAi Consortium centered at the Broad Institute.
Animal experiments
Mice were administered adenovirus via retro-orbital injection, and given WY 14,643 via
oral gavage or ip injection. Fasting experiments began at lights out and ended at the
indicated times. Activity measurements were performed in cages where infrared light
beams were placed every 1.5 inches along the length of the cage. Beam breaks were
measured using a digital counter. Body temperature was measured using an anal probe
accurate to 0.1 degrees Celsius. All experiments were carried out with approval from the
Committee for Animal Care at MIT and under supervision of the Department of
Comparative Medicine at MIT.
Image analysis
All quantification of fluorescent intensity, pixel location, and hepatocyte size were
performed using the NIH software ImageJ
Plasma and hepatic metabolite measurements
Ketones were measured using a colorimetric assay from Wako Chemicals. Serum
triglycerides were measured using reagents from Sigma. Non-esterified free fatty acids
were measured with a kit from Roche, while plasma insulin was measured using an
ELISA kit from DSLabs. Plasma glucose measurements were taken from tail blood using
an instant glucometer. All hepatic metabolite measurements were performed using
reagents from Sigma.
Quantitative RT-PCR
RNA was isolated from cells and tissues using Qiagen's RNeasy kit. Reverse
transcription of RNA into cDNA was performed using reagents from Invitrogen. Primers
for rt-pcr were obtained from Integrated DNA Technologies. Reactions were run on an
Applied Biosystems Prism machine.
Fatty-acid oxidation assay
Livers were removed from mice and three ~40 mg portions of liver were placed in
individual wells of a 24-well plate along with 1 ml of Krebs-Ringer saline and
radiolabeled oleic acid. Livers were incubated at 37 degrees Celsium and 5% oxygen for
2 hours. After two hours, the media was removed, and transferred to an eppendorf tube
with no cap. Tubes were placed in scintillation vials that contained 2 mls of water, and
incubated overnight at 65 degrees Celsius. The next day the vials were cooled down at 4
degrees for 30 minutes, the eppendorf tube was removed, scintillation fluid was added,
and then levels of deuterium in the water was measured in a scintillation counter.
In vitro ketogenesis protocol
AML12 cells were passaged in media prescribed by ATCC which contained insulin and
serum. For induction of ketogenesis, cells were grown to confluency, washed with PBS,
and incubated in media devoid of serum and insulin and containing 50 [M WY 14,643
and 2 mM sodium octanoate.
Chromatin Immunoprecipitation
Liver portions were crosslinked in 1.5% formaldehyde in PBS for 15 minutes at room
temperature, and the reaction was quenched with 0.125 M Glycine. Liver cells were
disaggregated using 20 gauge syringe needles. Resulting cells were then lysed in 1%
SDS lysis buffer for 10 minutes, then sonicated for 30 second intervals for a total of 5
minutes. Resulting lysates were diluted in buffers containing Triton, EDTA, NaCl and
Tris-HC1. Diluted lysates were pre-cleared with protein-A agarose/salmon sperm and
then incubated with antibody overnight at 4 degrees Celsius. The next day, antibody was
precipitated with protein-A agarose/salmon sperm for 1 hour, pelleted and subjected to
washes in low salt, high salt, LiCl and TE buffers in that order. The chromatin was
eluted from antibody with 1% SDS and 0.1 M NaHCO3, and crosslinks were reversed by
heating at 65 degrees Celsius for 4 hours. Resulting chromatin was treated with
proteinase K, purified using the High Pure PCR Template Preparation Kit from Roche,
and used for PCR analysis.
Immunofluorescence
Immunofluorescence for NCoR1 was performed as follows: Fixed tissue was embedded
in paraffin and processed onto slides for immuno-staining. Briefly, paraffin-coated
sections were de-waxed using EZ-DeWax deparrafinization solution (BioGenex),
blocked in PBS with 5% goat serum, stained overnight with antibody at 40 C, and then
incubated with Cy3-conjugated secondary antibody. Tiled images were obtained from an
inverted epifluorescence microscope (Zeiss) and intensity was quantified using ImageJ
(NIH).
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Figure Legends
Figure 1. Hepatic mTORC1 is feeding sensitive, and regulates liver size.
(A) Levels of phospho-S6 (ser240/44)) are sensitive to fasting and refeeding with normal
chow. Immunofluorescence of phospho-S6 (ser240/44)) (red) and Hoechst (blue) on
liver sections from mice. Quantification of fluorescent intensity of the rhodamine
channel representing phospho-S6 staining. (B) Western blots of liver protein lysates
show an time dependent increase in phospho-(S473)-Akt and phospho-(S240/244)-S6
upon refeeding following a 24 hour fast. Pre-treatment with rapamycin two hours before
refeeding blocks the increase in phospho-S6. (C) Western blots of liver protein lysates
from Tsc 1 and Raptor conditional mice show that presence of Cre recombinase leads to
loss of protein due to genetic recombination. (D) Liver knockout of Tscl (LiTsclKO) or
Raptor (LiRapKO) leads to insensitive mTORC1 signaling in response to feeding and
fasting. Livers from LiTsclKO mice show constitutive phosphorylation of S6, whereas
there is no detectable phospho-S6 in LiRapKO livers. (E) Gross images of increased and
decreased liver size in LiTsclKO and LiRapKO mice respectively. Liver mass from
mutant animals does not decrease in response to fasting. Quantification of liver weight
results from fed and fasted mice with percent change in weight listed at bottom. (F) The
change in liver size is due to changes in cell size. H&E stained sections of wild-type,
LiTsclKO and LiRapKO livers, and quantification of cell size in response to feeding and
fasting.
Table 1. Measurement of plasma metabolites reveal lower fasting ketone levels in
LiTsclKO Mice.
Plasma measurements were made from ten mice in each group with averages and
standard deviations listed. Fed mice were sacrificed at the beginning of the light cycle,
and fasted mice were sacrificed at the same time but after a 24 hour fast. Controla mice
are Tscl conditional mice injected with adenovirus not expressing any recombinant
protein. Controlb mice are insulin receptor conditional mice with no Cre transgene.
Controlc mice are Raptor conditional mice also with no Cre transgene. A * refers to
plasma values from mutant mice that are significantly (p < 0.05) different compared to
the appropriate control.
Table 2. Measurement of liver metabolites reveal a slight insulin resistant phenotype
in fed LiTsclKO mice and differences in hepatic TG levels in both LiTsclKO and
LiRapKO mice.
Hepatic metabolite measurements were made from 5 mice in each group with averages
and standard deviations listed. Fed mice were sacrificed at the beginning of the light
cycle, and fasted mice were sacrificed at the same time but after a 24 hour fast. Controla
mice are Tscl conditional mice injected with adenovirus not expressing any recombinant
protein. Controlc mice are Raptor conditional mice also with no Cre transgene. A *
refers to values from mutant mice that are significantly (p < 0.05) different compared to
the appropriate control.
Figure2. The defect in ketogenesis found in LiTsclKO mice is liver autonomous and
is due to repression of PPARox transcriptional activity.
(A) LiTsclKO mice have reduced plasma ketones after 24 hour fast, whereas wild-type,
LIRKO and LiRapKO mice exhibit elevated plasma ketones upon fast. (B) Injection with
the freely diffusible ketogenic substrate sodium octanoate in fasted mice does not rescue
decreased plasma ketone levels in LiTsclKO mice. (C) Ex vivo analysis of liver chunks
from fasted LiTsclKO mice show decreased oleic acid oxidation compared to wild-type
control livers. (D) Injection of sodium octanoate LiRapKo mice upon refeeding leads to
elevated plasma ketones in contrast to refed control mice. (E) Fasting-induced increased
in mRNA levels of PPARoc and its targets, Cptla, AOX, and HMGCS2 is blunted in
LiTsclKO livers compared to controls. However, levels of PEPCK and PK mRNA are
unaffected in LiTsclKO livers compared to controls. (F) mRNA levels of PPARo,
Cptla and HMGCS2 do not decrease upon refeeding for 2 hours in LiRapKO compared
to control mice.
Figure 3. Exogenous PPARoc synthetic ligand or overexpression of PPARoc cannot
rescue the ketogenic defect in LiTsclKO mice.
(A) Control and LiTsclKO mice were administered the PPARoc agonist Wy 14,643 via
oral gavage for five days consecutively, and then fasted for 24 hours. While synthetic
agonist increased plasma ketones in control mice, it had no significant affect on plasma
levels of ketones in LiTsclKO mice. (B) Quantitative RT-PCR of liver RNA reveals no
increase in mRNA levels of PPARoc or its targets in LiTsclKO livers compared to
control. PPARoc and HMGCS2 mRNA levels do increase with agonist treatment in the
small intestine of both control and LiTsclKO mice demonstrating efficacy of the drug.
(C) Stable infection of the mouse hepatocyte AML12 cell line with lentivirus expressing
short hairpins for GFP and Tsc 1 (shGFP and shTSC 1), and then incubation in ketogenic
media leads to a relatively small amount of ketone body production from shTscl infected
cells compared to shGFP infected cells. This cellular defect in ketogenesis can be
rescued by incubation with rapamycin (20 nM). Lentiviral expression of shTscl leads to
over a 60% reduction in Tscl levels in AML12 cells. (D) Adenoviral mediated
overexpression PPARoc in mouse livers in vivo or in AML12 cells (E) led to an increase
in ketone production in control cells, but did not rescue the ketogenic defect in LiTsclKO
mice or in AML12 cells infected with shTscl. Small graphs show level of PPAROC
overexpression.
Figure 4. Loss of Tscl in the liver leads to constitutive binding of the corepressor
protein NCoR1 to the PPRE of PPARoc, Cptla and HMGCS2 promoters.
(A) Chromatin immunoprecipitation with an antibody to NCoR1 reveals constitutive
binding at the PPRE in the promoters of PPARC, Cptla, and HMGCS2, whereas NCoR1
is not enriched at the promoters after a 24 hour fast in control livers. (B) ChIP
experiments using an antibody to p300 exhibit marked enrichment at PPARX target
promoters upon fasting in control mice, but relatively little enrichment at promoters from
LiTsclKO mice under fed or fasted conditions. (C) ChIP assay with an antibody to
acetylated histone H4 confirm p300 results by exhibiting dramatic enrichment at PPARX
promoters upon fasting in control livers, but little enrichment at promoters from
LiTsclKO mice under fed or fasted conditions. (D) Lentiviral-mediated knockdown of
NCoR-1 in shTscl-AML12 cells rescues the defect in ketone production due to Tscl
knockdown. Alternatively, treatment of shGFP, shNCoR-1, shTsc1, and
shTscl/shNCoR1 AML12 cells with the HDAC inhibitor trichostatin A (TSA, 100nm)
also rescues the ketogenic defect in Tscl knockdown AML12 cells.
Figure 5. mTORC1 regulates cellular location of NCoR.
(A) Immunofluorescent staining for anti-NCoR1 in paraffin-embedded liver sections. In
control livers, NCoR1 is found in both the nucleus and cytoplasm in fed animals, but only
in the cytoplasm after 24 hour fast. Quantification of NCoR1 intensity across the
diameter of hepatocytes. (B) NCoR1 is present in both the nucleus and cytoplasm in fed
and fasted livers from LiTsclKO mice. (C). Wild-type Raptor conditional mice exhibit
increased NCoR1 staining within the nucleus upon 1 hour of refeeding compared to
fasted mice where NCoR1 is primarily cytoplasmic. (D) The majority of NCoR1 staining
in livers from LiRapKO is cytoplasmic in both fasted and refed animals.
Figure 6. mTORC1 regulates aging-dependent changes in ketogenesis.
(A) Fasting of 2-8 month old Tscl conditional injected with adeno-cre does not result in
increased plasma ketones upon fasting as previously described. Conditional Tscl mice
18 months or older also exhibit decreased plasma ketones upon fasting, and injection with
cre, and subsequent loss of Tsc 1 does not result in an additional decrease in fasting
plasma ketones. (B) Quantitative RT-PCR of livers from old and young control and
LiTsclKO mice show that aged mice results in defective PPARX signaling similar to
young LiTsclKO mice, and loss of hepatic Tscl in old mice does reduce mRNA levels of
PPARoc or its targets further. (C) LiRapKO mice aged to 18-24 months do not exhibit
lowered plasma ketone levels upon fasting in contrast to aged controls. (D)Quantitative
RT-PCR show reveal that aged LiRapKO are protected from the aging-induced defect in
PPARoc-dependent transcription as seen in control mice. (E) Staining for NCoR1 in liver
sections from old mice reveal presence of NCoR1 in the nucleus in sections from both
fed and fasted mice in contrast to young mice (see Figure 5). Quantification of NCoR1
staining intensity by ImageJ reveal no significant change in NCoR1 localization upon
fasting in aged livers compared to young livers. (F) LiTsclKO mice do not exhibit
fasting-induced hyper-activity unlike their control littermates. Mice were placed in a
cage crisscrossed with infrared beams. Beam breaks due to mouse movement were
measured for 32 hours. (G) The body temperature of LiTsclKO mice plummet upon 48
hour fast compared to the modest decrease in body temperature seen in controls.
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Table 1
Glucose (mg/dl) Fed
Fasted
Insulin (ng/ml) Fed
Fasted
Fasting TG (mg/dl)
Fasting FFA (mM)
Fastinq ketones (mM)
Controla LiTscl KO Control b
112.3 ± 7.1
63.7 ± 6.8
2.33 ± 1.3
0.21 + 0.13
108 + 14.8
0.76 ± .05
0.37 ± 0.12*
96.9 ± 8.6
71.2 ± 4.8
4.10 ± 1.7
0.52 ± 0.21
92 + 10.4
1.1 ± 0.18
1.23 + 0.29
95 ± 10.6
66.8 ± 7.0
3.12 ±1.4
0.43 ± 0.27
83 + 12.3
0.81 ± 0.07
0.96 ± 0.19
LIRKO
339 ± 22.7*
110 15.4*
64.5 ± 9.5*
3.7 ± 0.86*
62 + 11.2*
0.64 ± 0.11*
1.59 ± 0.37
Controlc LiRapKO
94.2 ± 10.1
73.5 ± 12.6
3.21 ± 1.4
0.33 ± .17
77 + 16.9
0.31 ± .04
0.86 ± 0.13
102 + 8.4
71.5 + 12.7
2.84 + 1.5
0.24 + .13
108 ± 12.6
0.34 ± .04
0.91 ± 0.17
Table 2
Controla LiTscl KO Controlc  LiRapKO
Hepatic TG (mg/g) Fed 6.98 ± 0.41 5.39 ± 0.62 5.89 ± 0.52 5.18 ± 1.24
Fasted 20.86 ± 3.4 13.85 ± 1.6* 13.64 ± 2.4 6.56 ± 0.97*
Hepatic Glycogen (ug/mg) Fed 3.26 ± 0.39 1.83 ± 0.21* 2.86 ± 0.34 2.91 ± 0.34
Fasted 1.59 ± 0.17 2.27 ± 0.39 0.82 ± 0.12 0.76 ± 0.18
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A novel mouse model for the study of angiomyolipoma and
lymphangioleiomyomatosis, lesions found in TSC patients
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Summary
Lymphangioleiomyomatosis (LAM) and angiomyolipomas (AMLs) are unusual
and devastating lesions that occur primarily in young women, and are a leading cause of
death for patients with tuberous sclerosis complex (TSC). TSC is an autosomal dominant
disease that results from inactivating genetic mutations in either Tscl or Tsc2. The
biochemical consequence of either these mutations is increased mammalian target of
rapamycin complex 1 (mTORC1) signaling. AMLs are benign tumors with ectopic
proliferation of smooth muscle cells, increased deposition of fibrous tissue, adipose
tissue, and abnormally formed vascular channels. LAM patients experience progressive
destruction of their lungs by cyst formation and proliferation of smooth muscle-like cells.
The majority of LAM patients also have AML, and both lesions are diagnosed by
HMB45 positive staining. Here we describe a doxcycyline-inducible transgenic mouse
model where overexpression of the mTORC1 positive regulator Rheb2 in the mesentery
leads to cystic gowths with internal hemorrhaging, ectopic proliferation of multiple cell
types including smooth muscle cells and adipocytes, and expansion of HMB45 positive
mast cells. These results indicate that Rheb2 transgenic mice are a novel mouse model to
study the pathology of AML and LAM.
Introduction
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease with
an incidence of one in 6000 at birth, and is characterized by benign tumors (hamartomas
and hamartias) involving multiple organ systems (Kwiatkowski and Manning, 2005).
Although the disease has been described for over a century, our understanding of the
molecular pathogenesis of the syndrome has been limited. A major advance was made
with the discovery that TSC patients had inactivating mutations in either TSC1 or TSC2.
Work in Drosophila and mammalian systems have discovered that TSC1 and TSC2 form
an obligate heterodimer with GAP activity towards the small GTPase Rheb (Zhang et al.,
2003). When TSC1/2 GAP activity is inhibited by kinase-mediated phosphorylation,
Rheb, bound to GTP, activates TOR kinase activity when TOR is contained in complex
1. Three signaling pathways have thus been shown to regulate TSC1/2 GAP activity via
phosphorylation: the PI3K-Akt pathway, the ERK1/2-RSK1 pathway, and the LKB 1-
AMPK pathway. As a result, inactivation of TSC 1 or TSC2 in TSC patients leads to
constitutive activation of mTORC1 signaling.
The inactivating mutations in either TSC1 or TSC2 found in TSC patients consist
of the usual mix of nonsense, missense, insertion and deletion mutations, and show no
preference for a particular exon (Kwiatkowski and Manning, 2005). Mutations in TSC2
are fives time more frequent that mutations in TSC1 in TSC patients. However,
mutations in either are 100% penetrant. There are, however, differences in the severity of
the syndrome as measured by tissue involvement and mortality. Patients with mutations
in TSC1 seem to have a more mild form of the disease than those with mutations in
TSC2. Loss of one copy of either gene is sufficient to lead to disease manifestation,
although LOH has been found in some TSC tumor samples (Kwiatkowski and Manning,
2005).
TSC harmatomas have been found in patients at all developmental stages in life.
For instance, cardiac rhabdomyoma, a benign neoplasm of cardiomyocytes filled with
glycogen, is common in perinatal TSC patients but not as frequent in patients older than 5
years old (Isaacs, 2009). Despite having only benign tumors, TSC patients experience
accelerated mortality due to growths in the brain, kidney and lung that lead to a failure to
thrive, renal failure and respiratory failure respectively. The majority of TSC patients
have seizures that have been attributed to cortical tubers and subependymal nodules
present in the brains of TSC patients. The tubers of TSC are focal lesions with loss of
normal cortical cytoarchitecture and occurrence of abnormal enlarged neurons, glial cells
and less differentiated 'giant' cells (Crino and Henske, 1999).
While the brain phenotypes of TSC manifest early in age and sometimes last into
adulthood, the major clinical problems in TSC patients post puberty are the progressive
development of renal angiomyolipoma (AML) and pulmonary
lymphangioleiomyomatosis (LAM). Both proliferative lesions can arise spontaneously
but occur more frequently in TSC patients. 80% of TSC patients develop
angiomyolipomas (AMLs) by age 15 (Ewalt et al., 1998). AMLs are benign tumors
consisting of smooth muscle cells, fibrous tissue, adipose tissue, and abnormally formed
vascular channels (Gomez, 1999). AML is found more frequently in women at an
incidence of 1/300 compared to 1/5000 of male TSC patients (Ewalt et al., 1998).
Related to AMLs, LAM is an infiltrative, proliferative lung lesion composed of aberrant
smooth muscle and epithelioid cells with cyst formation and destruction of normal
airways (Moss et al., 2001). Patients with LAM eventually experience respiratory failure
as the disease progresses. Histologically, there are two primary components to LAM
pathology. Smooth muscle cell proliferation is seen within the lung parenchyma, with
cells varying from small round or oval cells, to small to medium spindle-shaped cells to
large epithelioid cells (Kelly and Moss, 2001; Sullivan, 1998). Surprisingly, all these
cells with variable morphology usually stain positive for smooth muscle actin, and are
thought to arise from a common progenitor cell. Second, there is progressive destruction
of connective tissue in the lung with the formation of cysts that are found thoughout the
lung of LAM patients (Matsui et al., 2000). As much as 63% of women with LAM,
sporadic or as part of TSC, also develop angiomyolipoma (Bernstein et al., 1995).
The diagnosis of angiomyolipoma and LAM is usually contingent upon imaging
results and positive staining of tumor biopsies with the monoclonal antibody HMB45.
The monoclonal antibody HMB45 was originally generated against an extract of human
melanoma cells (Hoon et al., 1994). The HMB45 antibody reacts with variably sized
proteins of the melanocyte-lineage gene SILV/PMEL17/GP100 (Du et al., 2003). In
lymphangioleiomyomatosis and angiomyolipoma cells, the binding sites for HMB45
antibody are cytoplasmic granules that resemble immature melanosomes (Matsumoto et
al., 1999). The reason for the occurrence of these HMB45 organelles in LAM and
angiomyolipoma cells is unknown.
Beyond the involvement of pathways affected by TSC1 and TSC2, there is
limited understanding of the pathogenesis of TSC and the related lesions LAM and AML
due to the difficulty of modeling the disease in rodents. The majority of mouse models
focus on the brain related phenotypes of TSC. Homozygote deletion of Tsc 1 or Tsc2
cannot be studied in the mouse due to embryonic lethality (Kobayashi et al., 2001). The
Eker rat arose as a spontaneous inactivating mutation in Tsc2 and develops brain
harmatomas, but with no TSC associated clinical phenotypes (Wenzel et al., 2004; Yeung
et al., 1997). Mice with conditional floxed alleles of Tsc 1 have also been generated
(Uhlmann et al., 2002). Using these mice, Tscl has been knocked out specifically in
astrocytes leading to the development of seizures and significant brain pathology.
However, this model does not produce pathology similar to that seen in TSC cortical
tubers (Uhlmann et al., 2002). When Tscl is deleted in most neurons beginning at
approximately embryonic day 13 (E13), mice experience spontaneous seizures, shortened
lifespan, and neuropathological abnormalities including ectopic, enlarged, and aberrant
neurons in multiple locations. These abnormal neurons have features similar to the
dysplastic neurons seen in TSC cortical tubers (Meikle et al., 2007).
Some mouse models have approximated certain aspects of LAM and AML found
in TSC. For example, both Tscl and Tsc2 heterozygous mice develop liver
hemangiomas consisting of proliferative smooth muscle cells, endothelial cells, and
vascular channels. Interestingly, hemangiomas occur more frequently and lead to
increased mortality in female mice compared to male mice (Kwiatkowski et al., 2002).
Consistent with this sex difference, expression of both the estrogen and progesterone
receptor were found in the liver hemangiomas. In the clinic, diagnosis of
angiomyolipomas and LAM are contigent upon positive staining with the monoclonal
antibody HMB45 by immunohistochemistry. Kwiatkowski et al. were unable to detect
HMB45 positive cells by immunohistochemistry, although they did detect reactivity to
the antibody by immunoblotting in some of the hemangiomas. Protein lysate from mouse
embryonic fibroblasts null for either Tscl or Tsc2 did not show the same result
(Kwiatkowski et al., 2002). Therefore, there must be some physiological context that
gives rise to this HMB45 positive population in angiomyolipomas and LAM. However,
identification of the cell of origin for these growths and the cells that give this unusual
antibody reactivity remains elusive. Given that angiomyolipomas in TSC patients
heterozygous for either Tscl or Tsc2 typically lose the other allele, the heterozygous
mouse may be too mild of a mutation to truly mimic the clinical manifestations of
angiomyolipoma and LAM.
A major impediment to the development of a mouse model of angiomyolipoma or
LAM is pinpointing the cell of origin. Angiomyolipomas have been found in multiple
tissues, and it is unclear whether LAM originates from a cell in the lung, or a circulating
metastasizing cell. To address these issues, we generated a transgenic mouse that
expresses the human Rheb2 gene in response to doxycycline administration. The
transgene was placed into the Col2A locus allowing for expression in a wide range of
tissues (Beard et al., 2006). Unpublished work from our lab demonstrated that
overexpression of the human Rheb2 transgene in mouse cells leads to constitutive
mTORC1 signaling similar to loss of Tscl or Tsc2. Our goal was to examine the
consequence of hyper-activation of mTORC1 in multiple tissues with the hopes of
modeling the development of angiomyolipomas and LAM in TSC patients.
Results
Generation and validation of a doxycycline-inducible Rheb transgenic mouse
Human (hs) Rheb2 transgenic mice were engineered by targeting murine
embryonic stem (ES) cells with frt homing sites placed in the Col2a locus with a plasmid
containing the transgene downstream of a tetracycline operator, and flanked by flp
recombinase sites. Additionally, the ES cells were previously engineered to contain the
tetracycline-inducible M2rtTA transactivator driven from the endogenous Rosa26
promoter (Beard et al., 2006). Treatment of the resulting ES cells with doxycycline
drove expression of hsRheb2 by the Col2a promoter. The engineered ES cells were then
used to generate chimera mice that were taken germline with subsequent breeding to
wild-type Black6 mice. Mice were bred to homozygosity for both the Col2a-tet-hsRheb2
and Rosa26-M2rtTA loci, and will be referred to as tetRheb2 while control mice only
containing the repressor element and will be referred to as M2rtTA.
Resulting tetRheb2 mice were given doxycycline either in their drinking water at
a dose of 2mg/ml, via intra-peritoneal (ip) injection once a week at a dose of 20mg/kg or
both avenues of doxycycline administration concomitantly. Doxycycline treatment of
tetRheb2 mice resulted in approximately 30-fold increase in human Rheb2 mRNA in the
intestine (Figure lA). Due to a lack of commercially available antibodies to Rheb2,
antibodies were generated in collaboration with Upstate Biotechnology. None of the
antibodies generated were able to detect endogenous human or mouse Rheb2 in multiple
human cell lines or mouse tissues. However, one antibody did detect overexpressed
Rheb2 in cell culture (Sancak, unpublished data). Using this antibody, overexpression of
hsRheb2 upon doxycycline treatment in transgenic mice was detected by immunoblotting
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and immunofluorescence in the liver, small intestine, and mesenteric tissue (Figure 1B
and 1C). Doxycycline inducible expression of hsRheb2 is also expected in the kidney,
testes, lymph nodes, spleen, thymus and the islet cells of the pancreas in transgenic mice
(Beard et al., 2006).
Rheb overexpression leads to hyper-activation of mTORC1 and multi-focal cysts
within the mesentery
tetRheb2 mice placed under a regimen of doxycycline in the water and via weekly
ip injection developed multi-focal cysts originating from the mesenteric tissue within 1
month of treatment (Figure 2A). The development of these cysts was specific to
transgene expression as treatment of M2rtTA mice with doxcycyline, or tetRheb2 mice
with ampicillin did not lead to cyst development (data not shown). Furthermore, removal
of doxycycline after 3 months led to complete regression of cyst formation (Figure 2A).
The penetrance of this phenotype varied depending on the sex of the mouse. Female
mice developed a large number of cysts, and exhibited poor body condition within 3
months of continuous doxycycline treatment, whereas male mice developed fewer or no
cysts and did not exhibit poor body condition within the same time frame (Figure 2B).
Mice administered doxycycline via water with no additional ip injections developed cysts
as well, but with a latency period of 5-6 months (data not shown), but the sexual
dimorphic aspect of the phenotype remained. Rheb2 overexpression also leads to
significant edema of the small and large intestines in the majority of transgenic mice, and
glomerular nephritis in approximately 20 percent of mutant mice (data not shown).
Dissection and subsequent immunofluorescent analysis of the cysts revealed that
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hsRheb2 was overexpressed throughout the cyst and surrounding mesenteric tissue
(Figure 2C). Staining of phospho-S6 revealed high levels that overlapped with high
Rheb2 staining throughout the mesentery and cysts (Figure 2C). These results
corroborate that cyst formation is due to overexpression of Rheb2 and hyper-activation of
mTORC1.
Cystic lesions in tetRheb2 mice have characteristics of AML and LAM
Histological analysis of the cysts found numerous abnormalities. After one month
of doxycycline treatment, the mesenteric tissue of transgenic mice showed increased
proliferation of both numerous cell types including mesenteric adipocytes indicative of a
lipoma (Figure 3A, top panel). Increased proliferation due to hsRheb2 overexpression
was also confirmed by phospho-Histone H3 positivity (Figure 3B). Also present in
mesenteric tissue upon doxycycline treatment were greater number of blood vessels, and
blood vessels with thicker walls (Figure 3A, middle panel). In contrast to the well-
defined and organized lymph nodes present in wild-type mesentery, transgenic mesentery
contained disorganized immune cell infiltrates present throughout both cystic and non-
cystic portions (Figure 3A, bottom panel). In addition, there was marked expansion of
mesenteric smooth muscle cells upon doxycyclin treatment (Figure 3C).
Mesenteric growths from tetRheb2 mice stain positive for HMB45
These histological and immunological findings from the Rheb2-overexpressing
mesenteric growths have many similarities with AMLs- benign mesenchymal tumors
found commonly in patients with tuberous sclerosis. Loss of function mutations in Tscl
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or Tsc2 is the most common genetic insult found in tuberous sclerosis. Biochemically,
we expect that overexpression of the small GTPase Rheb2 to be similar to losing Tsc 1 or
Tsc2, which as a heterodimer has GTPase activating function towards Rheb1 and Rheb2.
Therefore, we stained the cysts with clinical markers used to diagnose AMLs in human
patients. Diagnosis of AML depends on imaging and positivity with the melanocytic
marker HMB45. However, the exact cell type within the angiomyolipoma that stains
positive for HMB45 has not been clearly defined.
Women with tuberous sclerosis also have a high incidence of LAM. LAM is
characterized by progressive destruction of the lung by cyst formation and proliferation
of cells that stain positive for smooth muscle actin. Given that 50% of LAM patients also
have AMLs, it is thought that LAM may be caused by dessimination of AML tissue to
the lung. Accordingly, proliferative cells in the lungs of LAM patients also stain positive
for HMB45 and other markers of angiomyolipoma. Staining with HMB45 revealed a
robust increase in HMB45 positive cells in the mesentery of transgenic mice treated with
doxcycycline (Figure 4A and B). HMB45 positive cells were also positive for Rheb2 and
contained high levels of phospho-S6 (Figure 4B). Furthermore, the location of HMB45
positive cells was focused near regions of cyst formation. What cell type was staining
positive for HMB45?
The HMB45 positive cells are mast cells
The murine mesentery contains numerous different cell types, many of which
share characteristics with AML and LAM cells. For example, mouse mesenteric tissue
contains pre-adipocytes, smooth muscle cells, mast cells, other immune cells, adipocytes,
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stromal and squamous mesothelial cells. Many of the markers specific for each of these
cell types such as c-kit, tryptase, vimentin, desmin and smooth muscle actin, are reported
to also be present in both AMLs and in the lungs of LAM patients. The morphology of
the HMB45 positive cell was very distinct from many of the surrounding adipocytes and
stromal cells. Furthermore, HMB45 positive cells were present in wild-type mesentery,
although not nearly in the same number compared to transgenic mesentery treated with
doxycycline (data not shown). Staining with vimentin confirmed that HMB45 positive
cells were of mesenchymal origin, and not epithelial (Figure 4C). As a result, we
hypothesized that the HMB45 positive cells were native to the mouse mesentery, and
hsRheb2 overexpression leads to expansion of the population. The increase in population
of these cells also correlated to cyst formation. Given that previously published work had
shown that mast cells also stain positive for HMB45 in certain tumor types (Shidham et
al., 2003), we stained hsRheb2 overexpressing mesenteric tissue for mast cell markers.
Two common markers used for mast cells are c-kit and tryptase. C-kit (CD177) is a
membrane bound tyrosine kinase receptor that is present in melanocytic cells and has also
been reported to be diagnostic marker for angiomyolipoma (Makhlouf et al., 2002).
Tryptase is an abundant serine protease in mast cells, and staining for tryptase is used as a
marker for mast cell activation as well as presence. Of note, tryptase has been
characterized as a mitogen that promotes proliferation of fibroblasts and smooth muscle
cells.
We found that the HMB45 positive cells found in hsRheb2 over-expressing
mesentery co-stained with c-kit (data not shown) and tryptase (Figure 4D). This confirms
our initial hypothesis that the HMB45 positive cells in both the wild-type and transgenic
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mesentery are mast cells. The mast cells also co-stain with high levels of Rheb2 and
phospho-S6 indicating that overexpression of Rheb2 correlates with increased number of
mast cells in the mesentery.
In conclusion, we find that overexpression of hsRheb2 in the mesentery of mice
leads to cystic growths that can hemorrhage, proliferation of multiple cell types, and
expansion of HMB45 positive mast cells. This phenotype is more severe in female mice
as judged by both extent of cystic growths and latency of growth formation upon
overexpression of hsRheb2. In both male and female mice, these growths require
sustained overexpression of hsRheb2, for removal of dox leads to complete remission of
cystic growths within 1 month. Given that overexpression of hsRheb2 mimics the
genetic insult of losing Tscl or Tsc2 as found in patients with tuberous sclerosis, the
phenotype of the hsRheb2 transgenic mouse may serve as a clinically important mouse
model of tuberous sclerosis. Histological and immunohistochemical features of these
hsRheb2 dependent growths have many similar characteristics to angiomyolipomas and
LAM such as presence of proliferative blood vessels and proliferative smooth muscle like
cells, ectopic fat growth, and presence of HMB45 positive cells. Our identification of
these HMB45 cells as mast cells echoes previous findings describing mast cell staining in
angiomyolipomas and LAM, and highlights in importance of following up the possible
causal role mast cells may play in the development of LAM and angiomyolipomas.
Discussion
LAM is a devastating interstitial lung disease that occurs almost exclusively in
young women, and is the 3rd leading cause of death for patients with TSC. The majority
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of patients that develop LAM, sporadic or due to having TSC, also develop
angiomyolipomas. In these patients, both lesions have identical mutations in either Tscl
or Tsc2 and approximately 60% exhibit loss of heterozygosity of the remaining
functional allele (Carsillo et al., 2000). Furthermore, both lesions share numerous
histological characteristics such as presence of smooth muscle-like cells and cells that
stain positive for the melanocytic marker HMB45. Here we describe a mouse model
where overexpression of Rheb2 in the mesentery, the biochemical consequence of which
his similar to loss of Tscl or Tsc2, leads to ectopic proliferation of numerous cell types
including adipocytes, immune cells and smooth muscle cells. Furthermore,
overexpression of Rheb2 leads to increased presence of cells that stain positive for
HMB45. Despite being used as a consistent diagnostic marker for both LAM and AMLs,
the role of the HMB45 positive cell in the pathology of either lesion remains unclear.
Even the cell of origin for each lesion has eluded researchers of these growths. In our
transgenic Rheb2 mice, we find that the HMB45 positive cell is most likely a mast cell,
or a related cell that shares histological characteristics with mast cells. Our findings
support recent evidence of mast cell proliferation within the lungs of LAM patients and
highlight the importance of examining their functional role in the pathology of LAM and
AMLs.
The etiology of LAM and AMLs has puzzled researchers since the discovery of
the disease. Initial thoughts that LAM arose due to aberrant proliferation of a smooth
muscle cell native to the lung were challenged when a small percentage of LAM patients
who received lung transplants re-developed LAM in the transplanted lung (Karbowniczek
et al., 2003). This was also one of the first reports of LAM arising in a patient without an
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AML- challenging the perception that LAM could be a benign metastasis of the
angiomyolipoma to the lung. Recent work has correlated the multisystem manifestations
of LAM, both sporadic and within the TSC patient population, with a metastatic
dissemination of LAM cells (Carsillo et al., 2000) Genetic sequencing has allowed
researchers to identify cells that are found in renal, lymphatic and lung lesions of LAM
and TSC patients as having identical genetic mutations, and later finding these same
"LAM" cells in the blood and body fluids of LAM and TSC patients (Karbowniczek et
al., 2003). Thus, metastasis seems to be a mechanism by which LAM cells are
disseminated but the molecular determinants are unknown. The relationship between
mutations in the Tsc genes and many of the key features of LAM cells such as metastatic
capabilities, and the presence of smooth muscle-like and melanocytic characteristics is
also not clear.
Our finding that the HMB positive cell in the transgenic mesentery may also be a
mast cell echoes previous findings from LAM and TSC patients in the clinic. Mast cells
are best known for their role in IgE-dependent allergic diseases including asthma
(Kirshenbaum et al., 2003). Besides allergens, mast cells are also activated by pathogens
such as bacteria through their Toll-like receptors, and by stem cell factor (SCF) via the c-
Kit (CD117) receptor. In response to activation, mast cells produce a large array of
potent inflammatory mediators by several mechanisms including degranulation of pre-
formed compounds and production of numerous cytokines (Beaven and Baumgartner,
1996).
In addition to their role in inflammation, presence of mast cells correlates with
increased tissue fibrosis and angiogenesis. Mast cells found in areas of fibrosis and
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angiogenesis were found to secrete large amounts of the potent angiogenic and mitogenic
polypeptide basic fibroblast growth factor (bFGF) (Qu et al., 1995). This discovery was
very relevant for the study of LAM and angiomyolipoma, for bFGF is a powerful
mitogenic factor for smooth muscle cells and cells of mesodermal origin (Davis et al.,
1997). Mast cells are also the major source of the bFGF found in the lungs of chronic
pulmonary fibrosis patients (Inoue et al., 1996). Pulmonary fibrosis, although different in
etiology than LAM, shares the pathophysiologic features of SMA-positive cell
proliferation and extracellular matrix deposition (Inoue et al., 2002).
Examination by tryptase-positive staining found numerous mast cells within the
lungs of LAM patients. The mast cells were localized to the interstitium primarily, and
clustered around the spindle, smooth muscle cell-like proliferative LAM cells. In
addition, these mast cells were also positive for bFGF (Inoue et al., 2002). Later reports
confirmed this initial observation of mast cell presence in lungs of LAM patients.
Valencia et al. investigated the role of the renin-angiotensin system in LAM, and found
angiotensin II and ACE in proliferative spindle-shaped LAM cells. The authors also
found increased number of mast cells in the lungs of LAM patients compared to normal
lung, despite any evidence of inflammation within the diseased lung. They hypothesized
that chymase, an enzyme secreted by activated mast cells, could lead to formation of
angiotensin II, which in turn could stimulate proliferation of the LAM cells (Valencia et
al., 2006).
Consistent with our findings that hyper-activation of mTORC1 signaling by
overexpression of Rheb2 leads to increased number of mast cells, a recent report found
constitutive activation of mTORC1 in mast cells isolated from tumor samples.
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Furthermore, they found that rapamycin, an inhibitor of mTORC1 lead to decreased
survival and death of mast cells. Biochemical analysis confirmed that activation of mast
cells either through their IgE or c-KIT receptor led to activation of mTORC1 and
increased mast cell proliferation. This induction was significantly inhibited by rapamycin
(Kim et al., 2008). In conclusion, we believe that the Rheb2 transgenic mouse may serve
as a useful model of AML and LAM suffered by TSC patients. This model mimics the
sexual dimorphism of LAM, exhibits clinical diagnostic markers found in both AML and
LAM, and offers an in vivo system to study the role of mast cells in stimulating
proliferation of cells found in both lesions.
Experimental Procedures
Materials
The antibody to Rheb2 was obtained from Upstate Biotechnology. Antibodies to tryptase
and HMB45 were purchased from Abcam. Antibodies to c-kit were from Santa Cruz
Biotechnology, to Vimentin from Thermo Fisher, and antibodies to smooth muscle actin
were from Vector Labs. Doxycycline was purchased from Sigma.
Animal Experiments
When doxycycline was administered in the water, fresh batches were made once a week,
and were not supplemented with any type of sugar. To control for artifacts from weekly
ip injections, control mice were injected with PBS. Transgenic mice were generated in
collaboration with the Rippel Transgenic Facility with ES cells generously provided by
the Caroline Beard from the Jaenisch lab. All experiments were carried out with
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approval of the Center for Animal Care at MIT, and under supervision of the Division for
Comparative Medicine.
Histology and Immunofluorescence
Tissues were fixed in 10% neutral buffered formalin overnight, and then transferred to
70% ethanol. Tissues were processed, sectioned and stained for hematoxylin and eosin at
the Koch Institute histology core at MIT. Additional immunofluorescent staining and
microscopic imaging were performed in the following way: Briefly, paraffin-coated
sections were de-waxed using EZ-DeWax deparrafinization solution (BioGenex),
blocked in PBS with 5% goat serum, stained overnight with antibody at 40 C, and then
incubated with Cy3-conjugated secondary antibody. Tiled images were obtained from an
inverted epifluorescence microscope (Zeiss) and intensity was quantified using
CellProfiler.
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Figure Legends
Figure 1. Doxycycline induces overexpression of Rheb2 in multiple tissues.
(A) Quantitative RT-PCR of cDNA isolated from tetRheb2 intestines 6 hours after
doxycycline i.p. injection. Primers specific to human Rheb2 were used, and results
normalized to RT-PCR measurements of [3-actin mRNA. (B) Western blot of lysates
from liver, intestine and mesentery probed with anti-Rheb2 and anti-AKT antibodies. (C)
Immunofluorescent staining with anti-Rheb2 antibody of tissue sections taken from
tetRheb2 mice given normal water and PBS injections, or given doxycycline in the water
plus weekly doxycycline injections for 2 weeks.
Figure 2. Continual doxycycline treatment leads to tumor formation in tetRheb2
mice.
(A) tetRheb2 mice develop cystic tumors upon doxcycyline treatment in a time-
dependent manner. Removal of doxcycycline for 1 month in tetRheb2 mice with
palpable tumors leads to complete regression of tumor growths. (B) Quantification of
tumor development by quantification of cyst size. Development of cysts occurs with
shorter latency and greater number in female mice compared to male mice. (C)
Immunofluorescent staining of tumors reveals high expression of Rheb2 and co-staining
with phospho-(S235/236)-S6.
Figure 3. Tumors in tetRheb2 mice show proliferation of adipocytes, blood vessels,
and smooth muscle cells.
(A) H&E staining of mesenteric sections of M2rtTA and tetRheb2 mice treated with
doxycycline for 3 months. (B) Phospho-Histone H3 staining of mesenteric sections of
M2rtTA and tetRheb2 mice treated with doxycycline for 3 months. (C) Smooth muscle
actin and phospho-S6 staining of mesenteric sections of M2rtTA and tetRheb2 mice
treated with doxycycline for 3 months. Hoechst is used as a nuclear stain for all sections.
Figure 4. Tumors in tetRheb2 mice contain HMB45/Vimentin/tryptase-positive
cells.
(A) Immunofluorescent staining of mesenteric tumors from tetRheb2 mice treated with
doxycycline for 3 months reveal a population of HMB45/phospho-S6/Rheb2 positive
cells. (B) HMB45 positive cells stain positive also for Vimentin. (C) HMB45 positive
cells also stain positive for tryptase.
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Chapter 4
mTOR Complex 1 regulates whole-body growth and nutrient
sensing in the postnatal animal
Shomit Sengupta1 and David Sabatini1
1Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology
Department of Biology, Nine Cambridge Center, Cambridge, MA 02142
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Summary
Regulation of cell size impinges upon almost every cellular process, and in multi-cellular
organisms, impacts numerous physiological processes including organismal and organ
growth. The multi-component kinase mTORC 1 coordinates cell size with nutrient intake,
stress, growth factor and hormonal input and hypoxia. Reduction in mTORC 1 signaling
results in reduced organismal size in both Drosophila and mice owing primarily to a
defect in cell size. Given the ability to sense nutrients and to regulate organismal growth,
we aim to study the affects of mTORC 1 on nutrient-regulated postnatal growth and
identify tissues that utilize mTORC 1 to sense intake of food. We find that inhibition of
mTORC1 activity by the drug rapamycin severely diminishes postnatal growth in mice
due to a proportional decrease in most organs. This widespread affect is reflected by
results indicating that mTORC 1 is sensitive to feeding and fasting in almost all tissue
types. However, many tissues differ in the nutrient and hormonal stimulus that activate
mTORC1 upon feeding. In conclusion, we find that feeding activates mTORC1 in
almost every tissue and inhibition of this response in animals leads to pronounced
repression in postnatal growth.
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Introduction
Both prenatal and postnatal growth are tightly coordinated with nutrient
availability. In postnatal growth, the growth hormone (GH)/insulin growth factor-1
(IGF-1) axis is the dominant hormonal controller of body and organ size. While IGF-1
seems to mediate the majority of the growth promoting affects of GH, the two factors do
have some independent functions. This is most evident in the fact that a double knockout
(KO) of GH and IGF-1 is smaller than either KO alone (Lupu et al., 2001). In addition,
the hormone insulin also has growth promoting functions, for deletion of the insulin
receptor in specific tissues blocks growth of that respective tissue (Shiojima et al., 2002).
Both insulin and IGF-1 levels are affected by dietary intake (Breese et al., 1991), and
both activate PI3K signaling via their cognate receptors. The PI3K pathway controls
both cell size and number. Down-regulation of the insulin receptor or PI3K in
Drosophila results in small flies with fewer and smaller cells (Potter and Xu, 2001), while
overexpression or either protein leads to larger flies with more and larger cells (Saucedo
and Edgar, 2002). Downstream of PI3K signaling, the control of cell proliferation and
size begin to diverge. PI3K activation leads to activation of Akt, mTORCland numerous
other downstream effectors. Manipulation of Akt signaling modulates growth in
Drosophila (Verdu et al., 1999), and mice (Chen et al., 2001), although there is tissue-
dependent variability effect on cellular proliferation. While the growth promoting actions
of Akt is now well established, the contribution of mTORC signaling, dependent and
independent of Akt, is less clear.
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There is increasing evidence for the role of mTORC1 in regulating organ and
organismal size. Deletion of the mTORC1 substrate S6 kinase 1 (S6K1) in Drosophila
and mice result in decreased body size (Montagne et al., 1999; Shima et al., 1998) due to
primarily decreased cell size. Mouse embryonic fibroblasts isolated from S6K1 null
embryos exhibited no proliferation defect (Shima et al., 1998) indicating that the control
of cell proliferation downstream of P13K signaling may not go through the mTORC I1
branch in most tissues. Whole body deletion of4E-BP1, another mTORC1 substrate, in
mice does not exhibit reduced body or organ size with the exception of adipose tissue
(Tsukiyama-Kohara et al., 2001). The results in mice indicate that much of the growth
promoting effects of mTORC1 are through its substrate S6K.
As a regulator of cell growth, mTORC1 can respond to not only input from PI3K,
but also to nutrients such as amino acids directly. As such, it is important to understand
the contribution of each signal to the growth promoting actions of mTORC 1 in individual
tissues. However, dissecting these multiple inputs into mTORC1 has been a challenge
because it was not known which proteins mediate nutrient activation of mTORC 1
independent of PI3K activation. As a result, all the mutations in the mTORC 1 pathway
thus far have targeted components of the pathway that are shared between PI3K and
nutrient-stimulated activation. Now, with the discovery that the Rag proteins mediate
amino acid stimulation of mTORC I (Sancak et al., 2008), it will be interesting to see the
physiological impact of Rag mutations on postnatal growth.
Here we describe how inhibition of mTORC 1 using rapamycin dramatically
reduces postnatal growth in mice. However, this reduction in growth by rapamycin is not
seen in mice whose postnatal growth has already been blunted due to dietary restriction.
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To understand which tissue types mediate the feeding responsive actions of mTORC 1,
we compared tissues from mice refed for short periods of time following a fast with mice
injected with insulin, branched chain amino acids (BAA), glucose or both BAA and
glucose following a fast. By quantifying staining of phospho-S6 as a proxy for mTORC1
activity, we were able to determine which tissues activate mTORC1 in response to insulin
or nutrients, or a combination of the two. We obtained some surprising and novel results,
which allow us to build hypotheses for possible tissue-specific roles for feeding-
responsive mTORC1 signaling.
Results
Rapamycin inhibits postnatal growth.
Mice experience postnatal growth from birth to approximately 12 weeks of age,
with puberty occurring approximately between week 3 and 4. To determine the
consequence of mTORC 1 inhibition on early postnatal growth and pubertal growth,
rapamycin (10mg/kg in PBS) was administered daily to 3 week old male mice via intra-
peritoneal (ip) injection for one entire week. While control PBS-injected mice gained on
average 6 grams over the course of the week, rapamycin treated mice only gained an
average 3 grams- a 50% decrease (Figure lA). 3-week-old mice were also placed under
dietary restriction for one week, which resulted in no significant weight gain regardless of
whether they were treated with rapamycin. This latter result confirms that dietary
restriction leads to inhibition of mTORC 1 such that rapamycin treatment no longer has an
effect on growth (Figure lA).
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After the one-week period, mice were sacrificed and body weight and organs
were weighed to measure whether rapamycin inhibited all organ growth proportionally.
Rapamycin disproportionately decreases the size of the testes, thymus and spleen
compared to PBS-injected controls (Figure IB). It is unclear whether this reduction in
size of these organs is due to cell death, decrease in proliferation, or just decrease in size.
Immunoblots were then performed for phosphorylation of S6, a downstream
target of the mTORC 1 substrate S6K, to confirm the efficacy of rapamyin inhibition on
mTORC1 in vivo. As expected, S6 phosphorylation is reduced in all tissues assayed upon
rapamycin treatment. Shown here are results for liver, adipose, skeletal muscle, and heart
(Figure 1C). When activated, mTORC1 can suppress PI3K signaling as part of a
negative feedback loop. As a result, it is expected that rapamycin treatment would
abolish this negative feedback loop resulting in increased activation of PI3K signaling as
seen by increased phosphorylation of Akt. Consistent with the negative feedback loop,
we did see an increase in Akt phosphorylation in many tissues (data not shown).
However, in adipose, thymus, lungs and heart, phosphorylation of Akt is blunted upon
rapamycin treatment (Sarbassov et al., 2006). This is now understood to be due to
chronic rapamycin treatment induced disassembly of mTORC I1, which is the hydrophobic
kinase for Akt (Sarbassov et al., 2006).
Feeding stimulates mTORC1 in the liver and pancreatic islet cells through different
mechanisms.
Having established that mTORC1 inhibition by rapamycin can blunt postnatal
growth significantly in essentially every tissue, the question remains- what exactly does
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mTORC1 sense in each tissue? Given that mTORC1 has evolved to respond to numerous
stimuli such as hypoxia, amino acids, growth factors, and insulin, one may expect that
each tissue could utilize mTORC1 sensing and response in a unique manner. To answer
this question, we performed a simple screen using wild-type male mice. Mice were
fasted for 24 hours, and then refed for 15, 30, and 45 minutes. Tissues were then
harvested and stained for phosphorylation of S6- a proxy of mTORC1 activity. As
expected, numerous fasted tissues stained for low amount of phospho-S6, and refeeding
caused a time-dependent increase in the level of phosphorylation of S6 (Figure 2-4). Pre-
treatment with rapamycin before refeeding does block the increase in phospho-S6, thus
validating the immunofluorescent staining (data not shown).
To ascertain which aspect of refeeding, the food itself or the subsequent increase
in insulin, was directly stimulating mTORC 1 in each tissue, fasted mice were given ip
injections of glucose, branched-chain amino acids (BAA), both glucose and BAA, or
insulin. Mice were then sacrificed at 15, 30 and 45 minutes post injection and levels of
phosphorylated S6 were measured in all tissues. The intensity of the phospho-S6
immunofluorscent signal from each treatment was quantified by the image software
package CellProfiler (Carpenter et al., 2006), and normalized to levels ofphospho-S6 in
tissues from fasted mice. We also checked plasma insulin upon injection of BAA, and
found levels below 2 ng/ml at all time points, compared to levels near 10 ng/ml reached
post refeeding (data not shown). Amino acid injection also did not increase levels of
phospho-AKT in all tissues assayed (data not shown). This simple paradigm illuminated
a very interesting diversity in stimuli for mTORC 1 in individual tissues. In the liver, for
example, we find that the refeeding response of mTORC 1 can be approximated by either
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injection with insulin or BAA, implying that mTORC1 in the liver can respond to both
insulin and BAA (Figure 2A). In the pancreatic islet cells by contrast, only a
combination of glucose and BAA were able to phenocopy the refeeding-induced increase
in phospho-S6, whereas insulin had no effect (Figure 2B).
Feeding stimulates mTORC1 in the small intestine and testes independent of insulin.
The results in the intestine are slightly more complicated. The ip injections of
glucose, BAA, the combination of the two, or insulin did not phenocopy the increase in
phospho-S6 staining within the epithelial enterocytes upon refeeding (Figure 3A). This
result implies that the mTORC 1-activating stimulus must either come from the lumen of
the intestine, or involve some other aspect of chow not approximated by the injections.
However, insulin, glucose, and glucose plus BAA injections did cause an increase in
phospho-S6 levels within the paneth cells- found towards the bottom of the intestinal
crypts (Figure 3A). This unusual result indicates that the circuitry upstream of mTORC 1
can be diverse even within one tissue type. A similar result was seen within the
seminiferous tubules of the male testes. Refeeding fasted mice with chow resulted in a
robust increase in phospho-S6 levels within the interstitial cells and some of the cells that
line the tubules (Figure 3B). The injections were unable to phenocopy this refeeding
result, except for a modest increase in phospho-S6 within cells that line the tubules upon
BAA injection- with or without glucose (Figure 3B). This finding indicates that the
interstitial cells, the majority of which are testosterone-secreting Leydig cells, respond
either to a nutrient or combination of nutrients and other factors not mimicked by any of
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the injections. This result is particular interesting given the disproportionate reduction in
size of the testes caused by rapamycin treatment (Figure IB).
Feeding stimulation of mTORC1 differs between the spleen and thymus.
Although rapamycin treatment dramatically reduced the size of the thymus and
spleen, both tissues seem to regulate mTORC 1 differently. In the medulla of the thymus,
none of the conditions, with the exception of rapamycin, altered the high level of
phospho-S6 staining (Figure 4E). As a result, it seems that mTORC1 phosphorylation of
S6K within the thymus is feeding insensitive. The red pulp of the spleen, however,
shows dramatic modulation of mTORC1 in response to refeeding following fast. This
result can be mimicked by injection of BAA but not glucose or insulin. Similar to the
islet cells, it seems that mTORC 1 in the spleen is not downstream of insulin signaling,
but rather directly or indirectly downstream of amino acid signaling (Figure 4C).
Discussion
The genetic postnatal growth program is tightly coordinated with nutrient intake.
Malnutrition leads to stunted growth, whereas an energy rich diet can augment the growth
program. Here we find that inhibition of mTORC 1, a master regulator of cellular growth,
can suppress postnatal growth by mimicking reduced nutrient intake. The reduction in
growth affects every tissue, with some tissue being particularly sensitive to mTORC 1
inhibition. While we find that eating activates mTORC 1 in almost all tissues, there is
tissue-to-tissue variability in the activating stimulus. Here we discuss possible functional
roles for mTORC1 in tissues where feeding stimulated mTORC1 in unexpected ways.
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Pancreatic islet cells
Our findings that glucose and BAA activate mTORC1 in an insulin-independent
manner in islet cells confirm earlier reports in both rodent and human islets (Kwon et al.,
2004; McDaniel et al., 2002; Xu et al., 1998). However, the role ofmTORC1 in islet size
and function continues to be actively researched. Mice null for the mTORC 1 substrate
S6K1 are born with decreased islet mass (Shima et al., 1998). This reduced islet mass
correlates with decreased insulin production. Rapamycin inhibits beta-cell proliferation
in vitro and blocks the effect of Akt activation on beta-cell proliferation (Kwon et al.,
2006; Liu et al., 2009). Gain of function mutations in mTORC1 signaling in P-cells leads
to hypertrophy, increased insulin synthesis and release, and consequent hyper-
insulinemia (Mori et al., 2009). However, mTORC1 does not seem to impinge upon
glucose-stimulated insulin secretion. At nanomolar concentrations of rapamycin that
inhibit mTORC 1 activation by glucose in beta-cells, subsequent insulin secretion is not
affected (Kwon et al., 2004). However, rapamycin does not fully inhibit all mTORC 1
function (Thoreen et al., 2009), so more research is needed to test the role of mTORC 1 in
13-cells.
Epithelial cells of the small intestine
The stem cells located within the crypts of the small intestine give rise to 4
different cell lineages. Three of these lineages, absorptive enterocytes, mucus-secreting
goblet cells, and hormone-secreting enteroendocrine cells, migrate out of the crypts into
adjacent villi and have a relatively short lifespan of 3-5 days. The fourth lineage, paneth
cells, migrate to the base of the crypt, survive for over 30 days, and secrete a variety of
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anti-microbial peptides and proteins (Huynh et al., 2009). We find that refeeding leads to
a robust activation of mTORC 1 in all of these cell types. However, the presence of just
insulin in the blood is sufficient to activate mTORC 1 in the paneth and goblet cells,
whereas a luminal signal is probably required for activation of mTORC 1 in the
absorptive enterocytes. This division in stimuli between the different cell groups could
be due to their functional differences. The action of mTORC1 within the absorptive
enterocytes could affect nutrient absorption and/or transport of nutrients into the portal
circulation. Indeed, rapamycin has been shown to inhibit glucose and fat absorption
within the small intestine in rats (Yanchar et al., 1996). The molecular mechanism
behind these results is not known. It is also not known whether mTORC1 regulates
survival and/or the large amount of protein synthesis found in paneth cells. Recent
advances allowing for specific genetic manipulation within the intestinal stem cell niche
will hopefully allow more sophisticated analysis of mTORC 1 signaling within the small
intestine (Barker et al., 2009).
Leydig cells
There have only been a few reports investigating the role of mTORC 1 in the male
reproductive system. Young male transplant patients who take sirolimus, a rapamycin
analogue, have experienced infertility and low sperm count with possible correlation to
low testosterone levels. Removal of sirolimus leads to a reverse of all parameters
measured, and the accidental pregnancy of the wife of one of the patients (Deutsch et al.,
2007). Immunostaining for phospho-S6 was performed in testes of male patients and
found positive staining of sertoli and some interstitial cells- staining that was reduced
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upon sirolimus treatment (Deutsch et al., 2007). Furthermore, rapamycin can block the
testosterone-induced hypertrophy of cardiomyocytes (Altamirano et al., 2009).
Metabolic health and reproductive function in mammals are tightly coordinated. As a
result, it would not be surprising ifmTORC1 played a major role in this coordination-
either at the level of reproductive hormones or in the response to androgens.
Thymus/Spleen
The marked reduction in size of the thymus and spleen by rapamycin is not very
surprising given the role of rapamycin as a potent immunosuppressant. However, we
found the majority of phospho-S6 staining within the red pulp of the spleen- the site of
red blood cell filtration and phagocytosis and monocyte reserves (Swirski et al., 2009).
Further work is needed to determine how feeding sensitive mTORC 1 regulates either of
these processes.
In conclusion, we established a potent role for mTORC 1 signaling in postnatal
growth, and find feeding sensitive mTORC1 signaling in numerous tissues.
Administering insulin and nutrients into fasted animals illuminated the wide range of
diversity in upstream stimuli for mTORC 1 in different tissues. These results are the first
step in building hypothesis for tissue specific roles for mTORC 1.
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Experimental Procedures
Materials
Rapamycin was obtained from LC Labs. Antibodies to phospho-S235/236 S6, phospho-
240/244 S6, and total S6 were obtained from Cell Signaling Technology. Cy3
conjugated secondary antibody was obtained from Invitrogen.
Animal work
Rapamycin (1 mg) was dissolved in 20 l of ethanol, which was then diluted with
Ringer's saline solution to a final concentration of 1 mg/ml directly before use. Three-
week-old male C57BL/6NTac (Taconic) mice were administered daily intraperitioneal
injections of 10 mg/kg rapamycin or the drug vehicle for 7 days. The vehicle- and
rapamycin-treated mice ate similar amounts during the 7-day treatment period and at
necropsy all mice had evidence of processed food in their stomachs and small intestines.
Mice placed under caloric-restriction were fed 60% of their ad libitum fed littermates at
the onset of the dark cycle each day. For measurement of the refeeding response, mice
were fasted for 24 hours, and then refed with normal chow, or injected intraperitoneally
with insulin (0.75 U/kg), glucose (750 mg/kg), or branched chain amino acids (Leucine
69 mg, Arginine 30mg, Isoleucine 36 mg per mouse). Mice were then euthanized with
C02, and organs were weighed and then fixed in 10% neutral-buffered formaldehyde
overnight, or harvested into RIPA buffer and homogenized with mechanical disruption
followed by sonication. Lysates from vehicle- and rapamycin-treated organ pairs were
normalized for protein content and analyzed by immunoblotting.
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Immunofluorescence staining of tissue sections
Fixed tissue was embedded in paraffin and processed onto slides for immuno-staining.
Briefly, paraffin-coated sections were de-waxed using EZ-DeWax deparrafinization
solution (BioGenex), blocked in PBS with 5% goat serum, stained overnight with
antibody at 40 C, and then incubated with Cy3-conjugated secondary antibody. Tiled
images were obtained from an inverted epifluorescence microscope (Zeiss) and intensity
was quantified using CellProfiler.
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Figure legends
Figure 1. Rapamycin inhibits postnatal growth in a feeding-sensitive manner.
(A) Three-week mice injected daily with rapamycin (10mg/kg) grow only 50% of
vehicle-injected control mice over the course of a week (n=6, p < 0.05). Both groups
were allowed to fed ad libitum (AL versus AL + Rapa). Age-matched mice fed 60% of
fed controls (CR) show no significant gain in weight over the course of the week.
Injection of mice under CR with rapamycin (10 mg/kg) results in no significant
additional decrease in body weight (n=5, p > 0.05). (B) Individual organs from vehicle
or rapamycin treated AL mice were weighed, and calculated as percent of total body
weight. Values obtained from individual mice were averaged and plotted as percent of
total body weight on a logarithmic scale. All organs weighed from rapamycin-treated
mice maintained their proportionality except for the spleen, thymus and testes. (C)
Rapamycin treatment blocks the feeding-induced increase in phospho-S6 in tissues.
Protein lysates were generated from tissues from mice fasted 24 hours, and then injected
with PBS or Rapamycin two hours before refeeding for 45 minutes. Normalized lysates
were immunoblotted for levels of total and phosphorylated S6 (serine 235/236). Shown
are representive samples from liver, white adipose tissue (WAT), skeletal muscle, and
heart.
Figure 2. The liver and islet cells of the pancreas upregulate mTORC1 in response
to food.
(A) Refeeding following a 24 hour fast leads to a robust increase in levels of phospho-
(serine 235/236)-S6 in liver as shown by immunofluorescent staining. Injection of fasted
mice with insulin or BAA also leads to a marked increase in phospho-S6 levels, although
a bit lower than refeeding. Glucose causes a modest increase in phospho-S6 levels.
Quantification of average phospho-S6 intensity over three replicates. (B) The islet cells
of the pancreas also show a dramatic increase in phospho-S6 levels upon refeeding.
Injection with insulin has no effect on phospho-S6 levels, but the combination of glucose
and BAA raises phospho-S6 levels to similar levels as refeeding. Quantification of
phospho-S6 immunofluorescent staining is shown.
Figure 3. Enterocytes of the small intestine and cells of the testes show feeding-
sensitive mTORC1 activity.
(A) Phospho-S6 levels are undetectable in fasted mice, and increase within 45 minutes or
refeeding in all cells of the small intestine. Injection of insulin only increases phospho-
S6 in paneth and goblet cells. Injection of glucose mimics the insulin response to a
degree. Injection of BAA has no effect on phospho-S6 levels in the small intestine. (B)
Interstitial cells of the seminiferous tubules also show a large increase in phospho-S6
upon refeeding. No other treatment mimics this refeeding response. Injection of glucose
and BAA activates selected sertoli cells inside the tubules, but has little effect on the
interstitial cells.
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Figure 4. Quantification of phospho-S6 intensity under different conditions in
multiple tissues.
(A) Skeletal muscle and heart (B) both show refeeding sensitive phospho-S6 staining and
insulin, glucose and BAA all are able to increase phospho-S6 staining in the fasted
animal. (C) The red pulp of the spleen shows an almost 4-fold increase in phospho-S6
staining upon refeeding following fast. Insulin had no effect on phospho-S6 staining
compared to fasted mice, whereas BAA with or without glucose increased phospho-S6
staining to levels comparable to refeeding with chow. (D) The cortex of the kidney and
the medulla of the thymus (E) both show robust staining of phospho-S6 under all
conditions with modest changes induced by other treatments.
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Chapter 5
Discussion and Future Directions
Summary
The multi-component kinase mTORC1 coordinates nutrient and growth factor
inputs with numerous downstream processes including protein translation, autophagy,
metabolism and cell growth. The work described here focuses on tissue-specific
functions of mTOR complex 1 (mTORC 1). We found that inhibition of mTORC
suppresses whole-body postnatal growth similar to the effect of reduced caloric intake.
We found that while feeding activates mTORC 1 in almost every tissue, the upstream
activating stimuli varied from tissue to tissue. Studies we performed using liver-specific
mTORC 1 gain and loss of function mutants further elucidated the role of mTORC 1 in
organ growth. Confirming our studies with rapamycin, we found that genetic activation
or suppression of mTORC 1 in the liver increases and decreases liver size respectively.
Moreover, both mutant livers are resistant to fasting-induced reduction in mass.
Rendering the liver insensitive to nutrients through liver-specific mTORC 1 activation and
suppression also had functional consequences. In response to starvation, a normal liver
shifts to fatty acid catabolism and generates ketone bodies that supplement lowered
glucose levels for use by peripheral tissues. We find that constitutive activation of
mTORC 1 prevents the liver from initiating fatty-acid oxidation and ketone production in
response to fasting. This reduction in fatty acid catabolism and subsequent synthesis of
ketones resembles malfunctions in the hepatic fasting response associated with aging.
We find this aging-dependent process is mediated by mTORC1 such that loss of
mTORC I1 function throughout an animal's adult life prevents the aging induced decrease
in ketogenesis upon fasting. This finding indicates that pharmaceutical manipulation of
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mTORC1 may be beneficial in battling metabolic disorders due to disease and aging. The
disease TSC in humans is initiated by loss of TSC1 or TSC2, which also results in hyper-
activation of mTORC1. The disease can involve development of multiple lesion types
including brain harmatomas, soft tissue angiomyolipomas (AMLs), and the destructive
lung lesion lymphangioleiomyomatosis (LAM). We engineered transgenic mice that
express Rheb2, an mTORC 1 activator, in a doxycycline-inducible manner. Over-
expression of Rheb2 led to cystic growths with characteristics of both LAM and AML.
We believe this transgenic mouse provides an important platform for studying the
pathology behind these lesions and a mouse model for therapeutic intervention for TSC.
The following section explores some of the new questions that have emerged from this
collective body of work.
Does mTORCI have non-autonomous roles in postnatal growth?
We find that rapamycin dramatically inhibits the growth of 3 week old male and
female mice. All tissues retained the same proportion to whole-body size except the
spleen, thymus and testes, which were disproportionately smaller in rapamycin-treated
mice. However, the use of rapamycin is problematic, for chronic administration
disassembles mTORC2 in some tissues (Sarbassov et al., 2006). As a result, we find
lowered phosphorylation of AKT in white adipose tissue, thymus, lung, and heart.
Therefore, we cannot rule out the possibility that inhibition of AKT contributed to the
growth defect in these tissues. These results raise the question of whether suppression of
mTORC1 affects the GH/IGF-1 axis. The levels of both hormones decrease in response
to dietary restriction (Breese et al., 1991) through an unknown mechanism. Does
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mTORC 1 regulate levels of either of these hormones in response to dietary restriction?
Given that GH stimulates transcription and secretion of IGF-1 from the liver (Lupu et al.,
2001), we examined the effect of TSC1 loss in the liver in 19 day-old animals. After
injecting mice with adenovirus expressing cre at day 19, we studied them for 3 weeks,
measuring body weight every 3 days. At the end of the 3 week period, mice were
weighed and sacrificed. Both female and male LiTsclKO mice had 40% larger livers
than control mice. Loss of hepatic TSC in young male mice increased their growth rate
by an average of 14% as measured by total weight gain. However, the growth rate did
not increase for young female LiTsclKO mice. Further examination of livers from male
LiTsc 1Ko mice found no change in transcription of IGF-1, IGF 1-binding protein 5
(IGFBP5), or acid labile subunit (ALS). The latter two genes encode for serum IGF-1
binding proteins. Serum levels of IGF-1 between control and young LiTsclKO mice
were also similar. This preliminary finding suggests that hyperactive hepatic mTORC 1
signaling may increase postnatal growth rate in a non-autonomous manner. This
experiment should be repeated, with a more careful analysis of PI3K signaling in
peripheral tissues and a more complete work-up of plasma metabolites.
What is the role of mTORC1 in pubertal growth?
Puberty is controlled by signals from the hypothalamus, pituitary and the gonads
making up the gonadotropic axis (Tena-Sempere, 2005). The onset of puberty and the
accelerated growth rate associated with puberty are both affected by nutritional status
(Leve et al., 2007). For example, dietary restriction in female rodents results in lower
luteinizing hormone (LH) and estrogen levels (Roa et al., 2009). Artificial stimulation of
146
hypothalamic mTORC 1 signaling partially rescues decreased (LH) secretion from the
pituitary in dietary restricted animals (Roa et al., 2009). We found that rapamycin
treatment dramatically reduces testes size in pubescent mice. Additionally, we observe
feeding sensitive phospho-S6 staining of the interstitial cells of the seminiferous tubules-
the location of testosterone secreting Leydig cells. What is the function of feeding-
sensitive mTORC1 signaling within the gonads? Does it coordinate nutrient status with
LH stimulated testosterone release from the gonads? Androgens are synthesized from
cholesterol, and reports have shown an important role for mTORC1 in both sterol sensing
and cholesterol biosynthesis (Porstmann et al., 2008); Peng T, unpublished). The recent
development of the Leydig cell line (DuMond et al., 2006) allows for in vitro studies of
mTORC1 signaling on testosterone release in response to LH. Conditional Raptor or
Tsc 1 mice crossed with mice expressing cre recombinase from a Leydig cell or ovarian-
specific promoter could also genetically test the role of mTORC 1 in androgen release.
Alternatively, rapamycin therapy in mouse models for hypergonadism could be explored.
Data showing that testerone-induced hypertrophy of cardiomyocytes is mediated by
mTORC I would indicate that rapamycin would suppress precocious onset of puberty and
accelerated growth rate due to hypergonadism (Altamirano et al., 2009). We hope our
preliminary findings coupled with published data will initiate research on how mTORC1
regulates the production and secretion of humoral growth-promoting factors from the
liver and gonads during postnatal development.
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How does mTORC1 regulate transcriptional changes?
We describe a novel link between mTORC 1 and PPARcx transcriptional activity.
In addition to our work, there are numerous reports linking changes in mTORC 1
signaling with transcriptional changes. All of these reports raise the question of how a
cytoplasmic kinase complex affects gene expression changes in the nucleus? One
possibility is that mTORC 1 is not exclusively cytoplasmic, but has a nuclear presence.
Research from the Puigserver lab explained rapamycin's reduction of PGC-1 
transcriptional activity by describing mTOR and Raptor binding to the transcription
factor YY1 (Cunningham et al., 2008). We describe a different mechanism for mTORC1
regulation of transcriptional activity. We find that mTORC 1 regulates PPARoc
transcriptional activity by modulating the localization of its transcriptional co-repressor
NCoR from the cytoplasm to the nucleus. However, we were unable to decipher the
exact mechanism behind this localization change.
How does aging affect mTORC1 signaling?
We find hyperactivation of NCoR by mTORC 1 also occurs naturally in livers
from old mice and correlates with decreased PPARoc activity. Accordingly, loss of
hepatic mTORC 1 signaling prevents aging induced malfunctions in liver metabolism.
Our data complements recent studies describing extended lifespan in animals via
decreased mTORC signaling (Harrison et al., 2009; Selman et al., 2009). While our
understanding of aging is constantly evolving, the role of aging in inducing epigenetic
and gene expression changes is well established (Gravina and Vijg, 2009). Does
mTORC1 play a role in these aging induced changes in gene expression and chromatin
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remodeling? Although this question can be approached either through a top-down or
bottom-up strategy, we chose the latter by first identifying genes whose expression was
altered by mTORC1 signaling and then studying proteins that regulate promoter activity
of these genes. An alternate approach would be to manipulate downstream substrates of
mTORC 1. This would require a system where combination genetics could be employed.
For example, we could establish AML12 cells with stably expressed shRNAs to both
TSC1 and S6K1 and measure induction of PPARoc transcriptional activity in our
ketogenic media. Restoration of PPARoc activity in these double knockout cells would
indicate that mTORC 1 regulates NCoR localization via S6K1. This method is
complicated by the presence of multiple S6Ks and 4EBPs. However, given that deletion
of only S6K1 was sufficient to extend lifespan, such an approach could generate
interesting results. To further study the molecular mechanism of how mTORC 1 regulates
aging, cells with premature or advanced aging mutations could serve as a valuable in
vitro system. For example, numerous studies have been performed in fibroblasts from
patients suffering from Hutchinson-Gilford progeria syndrome or restrictive dermopathy.
In addition, analogous mutations have also been made in mice to model both of these
human diseases. Both of these reagents could provide insight into the role of mTORCl
in aging. Indeed, a report last year reported that the premature aging found in a mouse
model of restrictive dermopathy correlates with induction of autophagy due to mTORC 1
inhibition (Marino et al., 2008).
Is there crosstalk between mTORC1 and SIRT1?
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The sirtuin family of proteins actively regulates aging in yeast, flies and
mammals. With work showing the role of mTORC1 in aging in yeast, flies and
mammals as well, we believe future research should explore convergence between these
two pathways. SIRT 1 intersects with PPAR signaling in multiple ways. SIRT 1 increases
oxidative metabolism in liver by deacetylation of PGC- 1 c and binding with PPARoc
(Purushotham et al., 2009). Additionally, SIRT 1 represses PPARy signaling in white
adipose tissue by docking with NCoR (Picard et al., 2004). The relationship between
SIRT and mTORC1 regulation of PPARoc needs further research. Our analysis of
LiTsc 1KO mice confirmed earlier reports that loss of Tsc 1 results in elevated levels of
PGC-1 oc and increased mitochondria number (Cunningham et al., 2008). Given that
PGC- 1 oc is a well-established co-activator of PPARoc, we were surprised to find that
despite elevated levels of PGC-1 oc, PPARoc activity was suppressed in Tscl null livers.
One possible explanation is that mTORC 1 suppresses PPARoc via inhibition of SIRT1,
which results in constitutive NCoR promoter presence. We measured SIRT 1 levels in
wild-type and Tscl null livers under fed and fasted conditions and found no differences.
Additionally, we measured levels of acetylated-p53 as a proxy for SIRT 1 activity, but the
results were inconclusive. Whether overexpression of SIRT 1 or treatment with
resveratrol, a SIRT 1 activator, in AML 12 cells deficient for TSC 1 rescues the ketogenic
defect should be tested.
What is the role of mast cells in LAM?
Our current work describes a correlation between the presence of mast cells and
formation of AML and LAM like lesions in our Rheb2 transgenic mice. However, we
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are unable to determine whether mast cells contribute to the formation of these growths
or are part of an inflammatory response triggered by the growths. To test this, transgenic
mice can be crossed to mast cell deficient c-kitW-sh/W-sh mice (Wolters et al., 2005).
Overexpression of Rheb2 in mast cell deficient mice will answer whether mast cells
contribute to the formation and/or progression of the lesions. We could also perform the
reciprocal experiment by isolating mast cells from Rheb2 transgenic mice, and injecting
them into the mesentery or lungs of immuno-compromised mice (Sonoda et al., 1986).
Administration of doxcycyline to the resulting mice to increase Rheb2 expression will
determine whether mast cells with hyper-active mTORC 1 signaling are sufficient to
induce formation of cysts and proliferation of adipose and smooth muscle cells. Finally,
there are multiple inhibitors that inhibit mast cell degranulation (Erin et al., 2006). We
could test whether inhibition of mast cell degranulation would suppress tumor and cyst
formation in the Rheb2 transgenic mice.
Conclusions
The last fifteen years have seen an explosion of research projects aimed at
elucidating mTOR biology. Recent research projects examining mTOR function within
the intact animal have produced dramatic results and many more questions. With so
many cellular processes linked to mTOR activity, it is likely that additional substrates of
mTOR have yet to be identified. The search and identification of new direct substrates of
mTOR will hopefully answer many mechanistic questions within the field. It may also
help identify whether activation of mTORC 1 by nutrients extends beyond amino acids.
Specifically, given our work and others' on the role of mTORC 1 in regulating the PPAR
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family of transcription factors, it is apparent that mTORC senses fatty acids and lipids
as nutrients. If this is true, it brings up numerous questions of how mTORC1 impinges
on the numerous functions of fatty acids, lipids and membranes within the cell and within
the organism. There are also efforts to generate additional pharmaceutical inhibitors of
mTOR. Use of these new compounds in both in vivo and in vitro studies will be a
valuable new tool to probe mTOR function. Every cellular process uses energy; therefore
the sensing and communication of energy status is fundamental to all aspects of biology.
The study of TOR, a master nutrient sensor, serves as a great vantage point by which to
then study the field of biology.
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